Literature DB >> 31333395

Meta-Analysis of Gene Expression and Identification of Biological Regulatory Mechanisms in Alzheimer's Disease.

Lining Su1, Sufen Chen2, Chenqing Zheng3, Huiping Wei1, Xiaoqing Song1.   

Abstract

Alzheimer's disease (AD), also known as senile dementia, is a progressive neurodegenerative disease. The etiology and pathogenesis of AD have not yet been elucidated. We examined common differentially expressed genes (DEGs) from different AD tissue microarray datasets by meta-analysis and screened the AD-associated genes from the common DEGs using GCBI. Then we studied the gene expression network using the STRING database and identified the hub genes using Cytoscape. Furthermore, we analyzed the microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and single nucleotide polymorphisms (SNPs) associated with the AD-associated genes, and then identified feed-forward loops. Finally, we performed SNP analysis of the AD-associated genes. Our results identified 207 common DEGs, of which 57 have previously been reported to be associated with AD. The common DEG expression network identified eight hub genes, all of which were previously known to be associated with AD. Further study of the regulatory miRNAs associated with the AD-associated genes and other genes specific to neurodegenerative diseases revealed 65 AD-associated miRNAs. Analysis of the miRNA associated transcription factor-miRNA-gene-gene associated TF (mTF-miRNA-gene-gTF) network around the AD-associated genes revealed 131 feed-forward loops (FFLs). Among them, one important FFL was found between the gene SERPINA3, hsa-miR-27a, and the transcription factor MYC. Furthermore, SNP analysis of the AD-associated genes identified 173 SNPs, and also found a role in AD for miRNAs specific to other neurodegenerative diseases, including hsa-miR-34c, hsa-miR-212, hsa-miR-34a, and hsa-miR-7. The regulatory network constructed in this study describes the mechanism of cell regulation in AD, in which miRNAs and lncRNAs can be considered AD regulatory factors.

Entities:  

Keywords:  Alzheimer's disease; long non-coding RNA; meta-analysis; microRNA; network; single nucleotide polymorphisms

Year:  2019        PMID: 31333395      PMCID: PMC6616202          DOI: 10.3389/fnins.2019.00633

Source DB:  PubMed          Journal:  Front Neurosci        ISSN: 1662-453X            Impact factor:   4.677


Introduction

Alzheimer's disease (AD) is the most well-reported neurodegenerative disease, and seriously affects patients' ability to perform daily activities. The characteristic pathological changes of AD are the formation of extracellular amyloid plaques by abnormal amyloid beta accumulation, the formation of intracellular neurofibrillary tangles by tau hyperphosphorylation, and neuronal loss with gliosis proliferation (Huttenrauch et al., 2018). The etiology and pathogenesis of AD have not yet been elucidated. To identify the genetic variation in AD, large cohort studies have been carried out. The expression of stromal interaction molecule 1 (STIM1) protein decreases with the progression of neurodegeneration in AD by triggering voltage-regulated Ca2+ entry-dependent cell death (Pascual-Caro et al., 2018). The cerebrospinal fluid levels of C-X3-C motif chemokine ligand 1 which is a chemokine expressed by neurons, are decreased in AD dementia patients compared with controls (Perea et al., 2018). Genome-wide association studies (GWAS) studies have also revealed that some single nucleotide polymorphisms (SNPs) contribute to AD disease onset. These include common variants such as estrogen receptor 1 (ESR1), presenilin 1 (PSEN1), cholinergic receptor muscarinic 2 (CHRM2), cholinergic receptor muscarinic 3 (CHRM3), apolipoprotein E (APOE), apolipoprotein C1 (APOC1), and choline acetyltransferase (CHAT) (Zhou et al., 2014; Liu et al., 2016; Bagyinszky et al., 2018; Chee and Cumming, 2018; Li et al., 2018), and also rare variants in genes such as eukaryotic translation initiation factor 2 alpha kinase 3 (EIF2AK3) (Wong et al., 2018). EIF2AK3 is a single-pass type 1 membrane protein, which represses global protein synthesis as an endoplasmic reticulum stress sensor (Liu et al., 2012). Several SNPs within EIF2AK3 appear to significantly increase the risk of AD (Liu et al., 2013), especially rs147458427, an SNP that changes arginine to histidine at amino acid 240 (R240H) (Wong et al., 2018). Although EIF2AK3 polymorphisms are related to a risk of delayed AD (Liu et al., 2013), their function in neurodegenerative diseases is not very clear. Different microRNAs (miRNAs) are also associated with the pathophysiology of several neurodegenerative diseases (Gaughwin et al., 2011; Zovoilis et al., 2011), including AD (Kumar and Reddy, 2018). miRNA-377 promotes cell proliferation and inhibits cell apoptosis by regulating the expression level of cadherin 13 (CDH13), thus participating in the development of AD (Liu et al., 2018). The level of miR-221 is downregulated in AD cases compared with controls, and it is potentially a new therapeutic target for increasing ADAM metallopeptidase domain 10 (ADAM10) levels in AD (Manzine et al., 2018). Long non-coding RNAs (lncRNAs) are widely reported to be associated with various physiological and pathological processes, such as neurodegenerative diseases (Wang et al., 2016; Wang D. Q. et al., 2018). Brain cytoplasmic (BC) RNA is a lncRNA present at higher levels in the AD-affected region of the brain than in normal brain (Mus et al., 2007), and overexpression of BC in AD may cause synaptic/dendritic degeneratio (Wang H. et al., 2018). miRNAs function by targeting mRNAs for cleavage or translational repression. lncRNAs may affect miRNA activity by chelating them, thereby upregulating the expression of the miRNA target genes. The study of gene regulatory networks is important for disease analysis (Rankin and Zorn, 2014). However, research on the association of these AD markers in the context of biological networks is limited. To understand AD correctly, regulatory networks involving genes, miRNAs, transcription factors (TF), and lncRNAs need to be studied.

Materials and Methods

Microarray Data Collection

We used “Alzheimer” as a keyword to search for gene expression studies from different brain tissues in the NCBI-GEO database (http://www.ncbi.nlm.nih.gov/geo/). Only original experimental studies that screened for genes differing between AD and healthy humans were selected. Our criteria were as follows: (1) the type of dataset was expression profiling by array; (2) the brain regions were the entorhinal cortex (EC), hippocampus (HIP), and medial temporal gyrus (MTG); (3) for each brain tissue dataset, the total number of available samples were ≥10. Finally, the samples from seven studies including three tissues (EC, HIP, and MTG) were screened out. We then performed a meta-analysis of three datasets from EC tissue (GSE48350, GSE5281, and GSE26927), five datasets from HIP tissue (GSE5281, GSE36980, GSE1297, GSE29378, and GSE48350), and two datasets from MTG tissue (GSE5281 and GSE84422). A detailed description of the microarray datasets is presented in Table 1. Detailed descriptions of the samples, including the brain regions, sex, and mean age, are provided in Table S1.
Table 1

Datasets used in the meta-analysis.

Brain RegionsGEO accessionSample size (AD/control)PlatformPMID
Entorhinal Cortex (EC)GSE48350AD = 15; HC = 39GPL570: Affymetrix Human Genome U133 Plus 2.0 Array23273601 (Berchtold et al., 2013)
GSE5281AD = 10; HC = 13GPL570: Affymetrix Human Genome U133 Plus 2.0 Array29937276 (Readhead et al., 2018)
GSE26927AD = 11; HC = 7GPL6255: Illumina humanRef-8 v2.0 expression beadchip25119539 (Durrenberger et al., 2015)
Hippocampus (HIP)GSE5281AD = 10; HC = 13GPL570: Affymetrix Human Genome U133 Plus 2.0 Array29937276 (Readhead et al., 2018)
GSE36980AD = 7; HC = 10GPL6244: Affymetrix Human Gene 1.0 ST Array23595620 (Hokama et al., 2014)
GSE29378AD = 31; HC = 32GPL6947: Illumina HumanHT-12 V3.0 expression beadchip23705665 (Miller et al., 2013)
GSE48350AD = 19; HC = 43GPL570: Affymetrix Human Genome U133 Plus 2.0 Array23273601 (Berchtold et al., 2013)
GSE1297AD = 22; HC = 9GPL96: Affymetrix Human Genome U133A Array14769913 (Blalock et al., 2004)
Medial temporal gyrus (MTG)GSE5281AD = 16; HC = 12GPL570: Affymetrix Human Genome U133 Plus 2.0 Array29937276 (Readhead et al., 2018)
GSE84422AD = 20; HC = 14GPL96: Affymetrix Human Genome U133A Array27799057 (Wang et al., 2016)

AD, Alzheimer's disease; HC, healthy control.

Datasets used in the meta-analysis. AD, Alzheimer's disease; HC, healthy control. Searches were executed up to October 2017.

Analysis of Individual Data

Background correction and normalization of each individual dataset were performed using Robust Multichip Averaging (RMA) (Taminau et al., 2012). The differentially expressed genes (DEGs) between AD and healthy control samples (HC) were computed using the limma package (Derkow et al., 2018) in R. Gene symbol probes without gene annotation were removed. When multiple probes were matched with the same gene, the average value was used as the expression value.

Meta-Analysis of DEGs

Datasets from the same brain region (EC, HIP, or MTG) were combined to perform the meta-analysis. Initially, the data files were normalized using RMA. The normalized datasets were then merged using Fisher's exact test in the MetaDE package (Wang et al., 2012). The differentially expressed genes (DEGs) between AD and HC were selected using a P < 0.05 as the cut-off (Figure 1). In addition, the heterogeneity tests and differential expression analysis for each gene were analyzed using the ES algorithm of the MetaDE package in R (Wang et al., 2012). When multiple probes were matched with the same gene, we chose the average fold change of each probe. The thresholds of homogeneity were set as meta fold change > 1, tau2 = 0, and FDR > 0.05. The genes with tau2 = 0 and FDR > 0.05 were considered homogeneous and unbiased, from which the genes with a P < 0.05 in the Fisher's exact test of the MetaDE package were selected as DEGs. Tau2 represents the difference among study samples and reflects the heterogeneity between studies. The smaller the tau2 value, the smaller the heterogeneity.
Figure 1

P-value vs. number of detected DEGs for individual analysis as well as meta-analysis. In each individual dataset, moderated-t statistics was used to generate p-values while adaptive weight and Fisher's methods were utilized to combine these p-values for meta-analysis. This figure is generated using the “MetaDE” package in R. (A) The datasets from Entorhinal Cortex; (B) the datasets from Hippocampus; (C) the datasets from Medial temporal gyrus.

P-value vs. number of detected DEGs for individual analysis as well as meta-analysis. In each individual dataset, moderated-t statistics was used to generate p-values while adaptive weight and Fisher's methods were utilized to combine these p-values for meta-analysis. This figure is generated using the “MetaDE” package in R. (A) The datasets from Entorhinal Cortex; (B) the datasets from Hippocampus; (C) the datasets from Medial temporal gyrus. In this study, sub-meta-analyses on males and females with GSEs from different tissues were performed. The methods of normalization, meta-analysis, heterogeneity detection of each gene and threshold for selecting DEGs were the same as above.

RNA-Seq Data Analysis

We searched for gene expression studies from the NCBI-GEO database according to our criteria. The criteria were: (1) original studies between AD and healthy humans; (2) the type of dataset was expression profiling by high-throughput sequencing; (3) the brain regions used were EC, HIP, and MTG; (4) RNA-Seq data with poor quality controls were excluded. Finally, one gene expression dataset was selected, GSE67333, which uses samples from hippocampi brain regions and is based on GPL11154 platform information. Detailed information on these RNA-Seq samples is shown in Table S2. The available analyzed expression profiles of GSE67333 were used (Moradifard et al., 2018).

Construction of the DEG PPI Network, and Identification and Further Analysis of the Hub Nodes

STRING is a protein interaction network analysis tool. The latest version of the STRING database is 11.0 (Szklarczyk et al., 2019), which covers more than 5,090 species and 24.6 million proteins and supports the upload of genome-level data sets. To determine which proteins encoded by the DEGs play a leading role in AD, the DEGs were subjected to STRING v.11.0 with medium confidence scores of 0.4. To identify the hub nodes, we visualized the protein–protein interaction (PPI) network using Cytoscape v.3.6.0 software and analyzed the topological properties of these nodes using the Network Analyzer tool based on the degree parameter (Shannon et al., 2003). Then we selected the nodes with high degrees and high closeness centrality values as hubs. The degree is the number of protein-specific interactions, and a high value reflects an important role in the network. The closeness centrality reflects the ability of nodes to influence other nodes in the network, which reveals the centrality of the node in the network.

Identification of DEGs Associated With AD and Other Neurodegenerative Diseases

The Gene Radar online tool in GCBI (Shanghai, China, https://www.gcbi.com.cn/gclib/html/index) mainly uses the disease classification in the Mesh database to mine correspondence between genes and diseases from the PubMed database. We used Gene Radar to identify the DEGs associated with AD and those associated with other neurodegenerative diseases.

Analysis of miRNAs Associated With the AD-Associated and Other Neurodegenerative Disease-Associated DEGs, and of lncRNAs Associated With These miRNAs

DIANA-Tarbase v.8.0, containing 670,000 unique experimentally-supported miRNA–gene pairs (Karagkouni et al., 2018), was used to analyze the miRNAs associated with the AD-associated and other neurodegenerative disease-associated DEGs. Then, the miRNAs associated with AD and other neurodegenerative diseases were filtered using the miRdSNP v.11.03 online database (Bruno et al., 2012). DIANA-LncBase Experimental v.2, which provides more than 70,000 low- and high-throughput experimentally-supported miRNA–lncRNA interactions (Paraskevopoulou et al., 2016), was used to examine interactions between lncRNAs and these miRNAs. In our study, experimentally validated (prediction score ≥ 0.90) lncRNAs in human brain tissue were selected.

Differentially Expressed miRNAs in AD by High-Throughput Data

High-throughput data on miRNAs in AD is rare, so we collected only one miRNA microarray dataset in GEO (GSE16759), which studied miRNA expression in AD patients and controls (Nunez-Iglesias et al., 2010). The differentially expressed miRNAs were screened using the GEO2R tool, which is an interactive web tool based on GEO query and limma R packages (Davis and Meltzer, 2007).

Analysis of Transcription Factors Associated With the AD-Associated/Other Neurodegenerative Disease-Associated DEGs and AD-Associated/Other Neurodegenerative Disease-Associated miRNAs

To study the molecular regulatory mechanisms in AD, we built regulatory networks comprising AD-associated/other neurodegenerative disease-associated DEGs, TFs associated with these genes (gTFs), AD-associated/other neurodegenerative disease-associated miRNAs targeting these genes, and TFs related to these miRNAs (mTFs). Information on the TF binding sites associated with these genes were studied using TRANSFAC (Fogel et al., 2005) based on the Match™ algorithm. The TRANSFAC database comprises eukaryotic transcription factors, DNA binding sites, and their effects on gene expression (Fogel et al., 2005). In our study, the matrix similarity score (MSS) and the core similarity score (CSS) were used to estimate the result. The threshold values of MSS and CSS for selection were both score = 1. Regulatory information on the TFs associated with these miRNAs was analyzed using TransmiR v.2.0 database, an updated TF–miRNA regulation database (Wang et al., 2010). In our study, the literature-curated TF–miRNA regulations and the TF–miRNA interactions from ChIP-Seq evidence in human neural tissue were selected.

Verification of FFL Between the Gene SERPINA3, hsa-miR-27a and TF MYC

In order to verify the positive finding, FFL between the gene SERPINA3, hsa-miR-27a, and TF MYC, we collected GSE16759 dataset, which jointly profiled mRNA and miRNA expression in AD patients and controls (Nunez-Iglesias et al., 2010). The differentially expressed mRNA and miRNAs were screened using the GEO2R tool (Davis and Meltzer, 2007). To further verify the positive finding, GSE46579 dataset which studied miRNA expression in AD patients and controls blood and GSE97760 dataset which studied mRNA expression in AD patients and controls blood were collected. The available analyzed expression profiles of GSE46579 were used (Leidinger et al., 2013). The differentially expressed mRNA were also screened using the GEO2R tool.

SNP Analysis of the AD-Associated DEGs

To identify the AD-associated SNPs, SNP analysis of the AD-associated DEGs was performed. We used miRdSNP v.11.03 (Bruno et al., 2012) and LincSNP v.2.0 (Ning et al., 2014) to identify AD-associated SNPs associated with AD-associated DEGs (Yousef, 2015) Chromosome locus and allele gene information associated with each of the SNPs were received from dbSNP database (https://www.ncbi.nlm.nih.gov/snp/?term=).

Results

Analysis of Individual Datasets

Each individual dataset selected for use in the meta-analysis were corrected and normalized using the oligopackage (Liu et al., 2018) in R. All results are shown in Additional Figures, parts of which are shown in Figure 2.
Figure 2

Cassette figures of the expression data after standardization.

Cassette figures of the expression data after standardization. To identify common DEGs in different brain regions between AD and healthy controls, microarray datasets (Table 1) from three different brain regions (EC, HIP, and MTG) were meta-analyzed using the “MetaDE” package in R. With the threshold of P < 0.05 in Fisher's exact test, 781 DEGs in the EC brain region, 1707 DEGs in the HIP brain region and 220 DEGs in the MTG brain region were obtained. Then, with the homogeneity thresholds of meta fold change > 1, tau2 = 0, and FDR > 0.05, the DEGs with P < 0.05 in the meta-analysis from each tissue were collected and are shown in Table 2. The final results identified 183 DEGs in the EC brain region (120 upregulated and 63 downregulated), nine DEGs in the HIP brain region (four upregulated and five downregulated) and 15 DEGs in the MTG brain region (14 upregulated and one downregulated). A total of 207 DEGs were identified between the AD and HC samples (Table 2). More details about the DEGs are presented in Table 3, including the meta-expression between AD and HC and the Qpval in the meta-analysis. These 207 genes were identified as DEGs for the subsequent analysis.
Table 2

DEGs of Alzheimer's disease in different brain regions.

Brain partitionUpDown
Entorhinal Cortex (EC)12063
Hippocampus (HIP)45
Medial temporal gyrus (MTG)141
Table 3

Diferentially expressed genes (DEGs) identifed in the meta-analysis of AD datasets.

Brain tissueGene symbolsMeta. fold changeMeta. FDRMeta. z-scoreBrain tissueGene symbolsMeta. fold changeMeta. FDRMeta. z-score
Down regulatedUP regulated
Entorhinal Cortex (EC)ABHD8−0.6955349420.6373374640.000948744Entorhinal Cortex (EC)ENPP20.440494470.4295511940.033759913
ACTR1A−0.5273100940.9189432590.01124593FAM133B0.7122764580.9207230210.000694549
ADAP1−0.8269788710.8764171618.7236E-05FAM189A20.4891579390.4105749250.018954003
ALDOA−0.3841456130.4251121030.062660907FANCL0.4705113070.9533867220.023061608
ATP13A2−0.7620356440.7665396780.000296769FBXO150.9935071290.7571294413.75657E-06
ATP5D−0.7236613340.5347089530.000580599FUT90.7807696190.8739357790.000212873
BRSK2−0.5337064120.9995738020.010248351GFAP0.3980187350.3767016550.054426496
BSG−0.5169250380.4135129630.013242341GTF2H50.6573252580.7893983140.001738459
C1QTNF4−0.4575089280.4313603850.027673846HERC50.5741394910.9472659690.005903665
C9ORF16−0.6045698270.5663871820.00393522HLA-A0.3738428170.580031960.069323817
CA11−0.5839529210.3791266020.005356457HLA-DMA0.5139141130.5871277730.013644294
CCDC3−0.534906910.4502612710.010464563HLA-DPA10.3537946920.6578985710.084630186
CHGA−0.5116341570.7061218330.013873028HSPB80.4648625590.7256687370.024925703
COX7B−0.6330588990.5225427660.002608732ID30.5564540240.759462880.007598297
CPLX1−0.4916976370.6547966360.017956424IFI160.5152235750.5899483060.013365473
DMTN−0.5170509390.545574470.013023207IFT800.6210597220.8638517540.00303072
DNM1−0.7489213620.8516169720.000365222IGSF60.5657237120.9352534460.006629518
EDF1−0.5904154650.799833810.004719509IQCK0.8244109530.7850041249.22448E−05
EIF5A−0.5618329670.7637205910.007062777IRF80.6665139320.4590485110.001602805
EPHB6−0.4739788630.9252867910.022141665KAT2B0.438955030.5728838210.034051256
FAIM2−0.391697120.4234349140.057746056KCTD120.4487548130.4228740610.030866516
FXYD7−0.6038906320.920411140.003888889KMT5B0.7222205650.5652740270.000604808
GABRA1−0.4469624280.9385609440.030608148LAP30.6000615290.7521072380.004131397
GAPDH−0.5431329060.9030405830.009132231LBR0.5453026280.6339868770.009041239
GNA11−0.5774166410.8435173640.005654896LIX10.52145950.7171129610.012268136
GNAS−0.6037461480.8495860580.003904333LPAR40.9213074590.6814358581.21045E-05
GNB5−0.4116301840.4460168460.046627431MAFB0.6450616040.5675302140.002210118
GNG3−0.5113523740.605116630.013986977MAN2A10.4305560720.5127464740.037462643
HCFC1R1−0.7791442430.9591870830.000221638MEGF100.4693474950.4685852170.023860088
HSPBP1−0.5261287120.8377990880.011457968MYBPC10.5023118120.5799985040.015894899
INA−0.3862885060.4077142330.061235913N4BP2L20.8984854850.8931814331.66959E-05
IPCEF1−0.4270950320.5680912930.039036647NFASC0.5199104020.471592050.012649219
KCNH3−0.6891631170.888727070.001033475NPL0.5850101890.9309526470.005073462
KCNS1−0.4205240540.7535193060.041720093NQO10.5839835380.8770517240.005170715
L1CAM−0.5372970730.8531728780.00989732NUP1330.6287056370.5354527060.002834544
MAP1A−0.6656350220.6620534610.001574005OGFRL10.737377420.9881791050.000443276
MIF−0.7260020130.6126234910.000561817P2RY10.6150412850.6195001580.003352534
MINK1−0.419017890.5122033460.042751064PALLD0.5526819730.7293157090.008066199
MLF2−0.6319685670.7297653540.002633776PCMTD20.7229050620.9962256130.000571834
MLST8−0.8086755990.4080015120.000135237PIGF0.7147489360.8311427210.00067827
NARS−0.5364698610.6221644290.010066784PLEK0.6310495940.920975130.002621254
NDUFV3−0.7505150020.9624659050.000351448PLSCR40.4990913410.4569192040.01664371
NPDC1−0.5601937080.8126107210.007166708PLXDC20.5634142880.6108621810.006953418
NPM2−0.6921717550.8927054730.000990483PPM1K0.6633552870.7947736590.001602805
NRGN−0.5436716990.7590366340.009171049PRDX10.4865330180.8755087070.018985308
NRSN2−0.6892956980.7974832450.001049336PRDX60.5284590650.8988735560.011077302
NRXN2−0.6580680880.6485300520.001734285PRPF38B0.7174122080.476721170.000668253
OTUB1−0.5106021620.8389212880.013990734PTPN130.7401200960.8474066510.000426997
PCSK1N−0.5772854360.7086292470.005726271PTTG1IP0.5289465610.5925648090.01120586
POLR2I−0.4472685750.7231367730.030829368QKI0.4824554100.569351080.020327239
PPFIA3−0.5880451430.5683615740.004924869RAB100.5715144280.964712410.006130729
RAD23A−0.7064973390.5037523240.000808498RB10.7713499130.703276280.000265047
RPH3A−0.6039704890.8318389890.003941481RBL20.5966545780.9558530170.004295016
SEZ6L2−0.7604238590.8458501740.000308039RHOBTB30.5172245910.6350222150.012995242
SLC17A6−0.5333016180.4309523350.010548042RNF19A0.5929856150.8112366790.004594707
SLC25A6−0.6551471690.6101827590.001839469SERPINA30.2601485070.4102521670.199003256
SYN1−0.5005312560.4017366590.01638868SFRP20.7100293050.9496939080.000717923
TMSB10−0.5326123240.6976639770.010507137SLC16A90.3828119180.3781959340.06339803
TNPO2−0.6146797850.9306253820.003314968SLC44A10.6381014750.7625203350.002367894
TOMM40−0.7389382870.9853606070.000431171SLC47A20.4534853640.5828977570.028596711
TUBB4A−0.4891354840.5906682670.018714834SMAD50.7273283410.6053459580.000553469
TUBB4B−0.5559337020.5812793940.007710577SMC30.7044139150.7484049350.000804324
USP11−0.4583792280.7488998190.026995158SMG10.7530300420.7468789080.000341013
Hippocampus (HIP)RPS27A−0.5063899680.4983685010.000441679SOX90.4264473860.8349719930.038857167
TPD52L2−0.4956255180.5136617260.000568354SPARC0.4344725510.9092925560.035391101
IFI27−0.4579661730.6862974990.001275153SPATA130.710206610.7280564640.000732949
HBB−0.3867010350.4206697940.005961549SPP10.4938816280.4523177820.017825778
NCAN−0.2371227920.4185709530.082322179SRSF60.4582073540.8318017690.026846982
Medial temporal gyrus(MTG)BAIAP3−0.6530663610.4353615270.006816604STARD70.4940669450.7742644890.017368311
STOM0.4546510400.4329908350.028810836
Up regulatedSUMF10.7456092270.9044391440.000385675
Entorhinal Cortex (EC)ACADM0.5093964460.4722817710.014636865TAC10.3910759960.4740315060.057949745
ACTL6A0.639895830.9183669260.002292345TJP20.5329714000.7506520890.010483346
ADAMTSL30.552180350.5264475360.008121713TMEM1230.626185710.6574108290.002886301
ADAP20.582019660.7416489890.00536564TPD52L10.4892603390.5065355120.018809583
AK30.6242956690.4362601020.003014442TPT10.3001334250.3682237770.141755572
AKR1C30.6102320890.969655440.003533684TRIM220.6785348390.8323210990.001261374
ALDH9A10.6328663640.754399150.002612489TRMT130.7937568830.3691977130.000174472
AMOTL20.5259921430.4398425410.011663327TSPAN60.6293238620.9344313250.002691794
ANGPT10.5413706260.9484712990.009286251UNC500.5380421890.6756477630.009896486
ANXA50.5190906790.4916641990.012875449VPS13C0.5755985170.3833725070.006035562
APBB1IP0.6080779870.9533558870.003667668WDR110.8387412190.8909457586.72009E-05
APLNR0.3706071230.8532303720.070987979WRN0.6976036320.5734790360.0009141
ARFGAP30.7016451530.6295059640.000882795ZFAND60.6695877690.7883274010.001442107
ARRDC40.5376241390.5021110860.00999833ZNF5360.4084086490.3971471190.048474831
ATG4C0.6247657610.4406661960.002969363ZNF7700.8755988580.4824284753.13048E-05
ATRAID0.6016031000.7754194520.004065448Hippocampus (HIP)PCSK1N0.2259741520.4165008140.09711283
B2M0.3530230460.5798302310.085440354GJA10.2522285680.6743050990.035832633
BBOX10.6449088980.4656404030.002237249MT1M0.2891850910.6032798370.035832633
BMI10.5420565510.6730437010.00935053PLSCR40.296916960.4063513630.031675355
C30.4216574920.8390377640.040981301Medial temporal gyrus(MTG)AEBP10.704643630.5216287590.003562337
C5ORF150.8047205460.7419205970.000134819AFFX-HUMRGE/M10098_3_AT0.3684442880.5112226920.120022659
CAPN20.5359827210.7608367990.010108106AFFX-HUMRGE/M10098_5_AT0.5508847030.4764938870.021509016
CAPS0.4832651120.5601117050.019921529AFFX-HUMRGE/M10098_M_AT0.4673659960.6237749620.050219844
CD810.515201380.8712133370.013160531COX170.8187290130.4271714370.000795487
CEBPB0.3803128090.3784715520.065611904EEF20.3867967080.3586800340.103799055
CLCA40.650551720.4349172610.002025628GOT20.4683167190.340992370.050357246
CLU0.4477789710.4487858480.030793889HBA10.7156321340.4858326390.003132774
CMTR20.6295662660.5529359040.00274856HSPB10.4703394790.6242184340.048780735
COMMD30.5344728880.710404710.010343935MT30.4691189420.4583109270.049672645
CP0.5233513290.7155312480.011868269NME20.6475383520.3534846530.007327162
CSRP20.5333890660.6533993150.010396527SEPP10.5178028280.4385898770.03046524
DDIT4L0.4619149040.9841522350.025550129SEPW10.4770432870.459080910.045928551
DOCK40.6843223380.5160023780.001146172ZBTB160.5156749960.3456198470.031356668
DYNLT10.6148528840.9380937090.003331664

The DEGs were listed based on homogeneity detection FDR and meta-analysis fold change. AD, Alzheimer's disease; HC, healthy control.

DEGs of Alzheimer's disease in different brain regions. Diferentially expressed genes (DEGs) identifed in the meta-analysis of AD datasets. The DEGs were listed based on homogeneity detection FDR and meta-analysis fold change. AD, Alzheimer's disease; HC, healthy control. A sub-meta-analysis on females and males was performed using datasets from each brain region (EC, HIP, and MTG). The results of the sub-meta-analysis of the EC brain region in males and females revealed that there were 217 DEGs in males (176 upregulated and 41 downregulated), of which 212 were male-specific, and 175 DEGs in females (five upregulated and 170 downregulated), of which 170 were female-specific (Table S3). Only five common DEGs were identified in females and males. The result of this analysis is also shown in a Venn diagram (Figure 3).
Figure 3

The number of common genes obtained from entorhinal Cortex (EC) in females and males visualized by a Venn diagram.

The number of common genes obtained from entorhinal Cortex (EC) in females and males visualized by a Venn diagram. The results of the sub-meta-analysis of the HIP brain region in males and females showed that there were 11 DEGs in males (one upregulated and 10 downregulated), and 28 DEGs in females (10 upregulated and 18 downregulated). No overlapping DEGs were obtained between females and males (Table S4). The results of the sub-meta-analysis of the MTG brain region in males and females showed that there were 293 DEGs in males (11 upregulated and 282 downregulated), and 30 DEGs in females (19 upregulated and 11 downregulated) (Table S5). Only one common DEG was identified in females and males. The result of this analysis is also shown in a Venn diagram (Figure 4).
Figure 4

The number of common genes obtained from medial temporal gyrus (MTG) in females and males visualized by a Venn diagram.

The number of common genes obtained from medial temporal gyrus (MTG) in females and males visualized by a Venn diagram.

Analysis of Gene Expression in AD by RNA Sequencing

To further validate the results from the microarray data with public RNA-Seq data, we selected datasets that used the same brain regions as the microarray datasets. Hence, the DEGs between AD and HC were analyzed in the GSE67333 RNA-Seq dataset. This revealed that 1102 DEGs were filtered from GSE67333 with a threshold of P < 0.05 and fold change ≥ 1.23 (Moradifard et al., 2018). Detailed information on these DEGs is shown in Table S6. Then, we analyzed the common DEGs between the RNA-Seq and microarray data, which revealed 72 common DEGs in the HIP brain region in both the RNA-Seq and microarray data.

Identification of AD-Associated or Other Neurodegenerative Disease-Associated DEGs

AD-associated and other neurodegenerative disease-associated genes were identified from the DEGs using the Gene Radar tool from the GCBI online software. Out of the 207 total DEGs, 57 had previously been shown to be associated with AD (AD-associated genes; 34 upregulated and 23 downregulated), and 43 DEGs had previously been shown to be associated with several other neurodegenerative diseases (other neurodegenerative disease-associated genes; 30 upregulated and 13 downregulated), such as multiple sclerosis, Parkinson's disease (PD) and Huntington disease (HD) (Table 4). Overall, the number of upregulated genes was greater than the number of downregulated genes. These AD-associated or other neurodegenerative disease-associated DEGs are important genes for further research. The detailed down/upregulated status of the 57 AD-associated DEGs in each individual dataset is provided in Table 5.
Table 4

AD and other neurodegenerative diseases associate genes identified from DEGs using GCBI online software.

Expressionin meta-analysisGene symbolBrain partitionGene nameCorresponding neurodegenerative disease
Down-regulatedADAP1ECArfGAP with dual PH domains 1AD
MLST8ECMTOR associated protein, LST8 homologAD
HCFC1R1ECHost cell factor C1 regulator 1AD
NDUFV3ECNADH:ubiquinone oxidoreductase subunit V3AD
DNM1ECDynamin 1AD
TOMM40ECTranslocase of outer mitochondrial membrane 40AD
RAD23AECRAD23 homolog A, nucleotide excision repair proteinAD
RPH3AECRabphilin 3AAD
FXYD7ECFXYD domain containing ion transport regulator 7AD
GNASECGNAS complex locusAD
PCSK1NECProprotein convertase subtilisin/kexin type 1 inhibitorAD
TUBB4BECTubulin beta 4B class IVbAD
NRGNECNeurograninAD
GAPDHECGlyceraldehyde-3-phosphate dehydrogenaseAD
L1CAMECL1 cell adhesion moleculeAD
BRSK2ECBR serine/threonine kinase 2AD
SLC17A6ECSolute carrier family 17 member 6AD
HSPBP1ECHSPA (Hsp70) binding protein 1AD
DMTNECDematin actin binding proteinAD
SYN1ECSynapsin IAD
GNB5ECG protein subunit beta 5AD
INAECInternexin neuronal intermediate filament protein alphaAD
RPS27AHIPRibosomal protein S27aAD
ATP13A2ECATPase 13A2PD
MAP1AECMicrotubule associated protein 1APD
SLC25A6ECSolute carrier family 25 member 6PD
ATP5DECATP synthase, H+ transporting, mitochondrial F1 complex, delta subunitMultiple sclerosis
MLF2ECMyeloid leukemia factor 2Multiple sclerosis
CA11ECCarbonic anhydrase 11Multiple sclerosis
ACTR1AECARP1 actin-related protein 1 homolog A, centractin alphaMultiple sclerosis
OTUB1ECOTU deubiquitinase, ubiquitin aldehyde binding 1Multiple sclerosis
EPHB6ECEPH receptor B6Multiple sclerosis
C1QTNF4ECC1q and tumor necrosis factor related protein 4Multiple sclerosis
ALDOAECAldolase, fructose-bisphosphate AMultiple sclerosis
EDF1ECEndothelial differentiation related factor 1Neurodegenerative disease
NARSECAsparaginyl-tRNA synthetaseNeurodegenerative disease
Up-regulatedSERPINA3ECSerpin family A member 3AD
SLC16A9ECSolute carrier family 16 member 9AD
TAC1ECTachykinin precursor 1AD
GFAPECGlial fibrillary acidic proteinAD
MAN2A1ECMannosidase alpha class 2A member 1AD
SRSF6ECSerine and arginine rich splicing factor 6AD
HSPB8ECHeat shock protein family B (small) member 8AD
MEGF10ECMultiple EGF like domains 10AD
PRDX1ECPeroxiredoxin 1AD
CPECCeruloplasminAD
PRDX6ECPeroxiredoxin 6AD
CAPN2ECCalpain 2AD
PLXDC2ECPlexin domain containing 2AD
IGSF6ECImmunoglobulin superfamily member 6AD
RAB10ECRAB10, member RAS oncogene familyAD
ADAP2ECArfGAP with dual PH domains 2AD
NPLECN-acetylneuraminate pyruvate lyaseAD
LAP3ECLeucine aminopeptidase 3AD
ATRAIDECAll-trans retinoic acid induced differentiation factorAD
APBB1IPECAmyloid beta precursor protein binding family B member 1 interacting proteinAD
DYNLT1ECDynein light chain Tctex-type 1AD
ARFGAP3ECADP ribosylation factor GTPase activating protein 3AD
FAM133BECFamily with sequence similarity 133 member BAD
IQCKECIQ motif containing KAD
WDR11ECWD repeat domain 11AD
CLUECClusterinAD
B2MECBeta-2-microglobulinAD
MT3MTGMetallothionein 3AD
SEPP1MTGSelenoprotein PAD
NME2MTGNME/NM23 nucleoside diphosphate kinase 2AD
EEF2MTGEukaryotic translation elongation factor 2AD
PCSK1NHIPProprotein convertase subtilisin/kexin type 1 inhibitorAD
MT1MHIPMetallothionein 1MAD
GJA1HIPGap junction protein alpha 1AD
STARD7ECStAR related lipid transfer domain containing 7PD
MYBPC1ECMyosin binding protein C, slow typePD
AMOTL2ECAngiomotin like 2PD
VPS13CECVacuolar protein sorting 13 homolog CPD
RNF19AECRing finger protein 19A, RBR E3 ubiquitin protein ligasePD
NUP133ECNucleoporin 133PD
PCMTD2ECProtein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 2PD
HLA-AECMajor histocompatibility complex, class I, AMultiple sclerosis
ZNF536ECZinc finger protein 536Multiple sclerosis
STOMECStomatinMultiple sclerosis
QKIECQKI, KH domain containing RNA bindingMultiple sclerosis
CAPSECCalcyphosineMultiple sclerosis
SPP1ECSecreted phosphoprotein 1Multiple sclerosis
ACADMECAcyl-CoA dehydrogenase, C-4 to C-12 straight chainMultiple sclerosis
HLA-DMAECMajor histocompatibility complex, class II, DM alphaMultiple sclerosis
NFASCECNeurofascinMultiple sclerosis
PLEKECPleckstrinMultiple sclerosis; HD
ACTL6AECActin like 6AMultiple sclerosis; PD
GTF2H5ECGeneral transcription factor IIH subunit 5Multiple sclerosis
IRF8ECInterferon regulatory factor 8Multiple sclerosis
TRIM22ECTripartite motif containing 22Multiple sclerosis
PRPF38BECPre-mRNA processing factor 38BMultiple sclerosis
KMT5BECLysine methyltransferase 5BMultiple sclerosis
AK3ECAdenylate kinase 3HD
PPM1KECProtein phosphatase, Mg2+/Mn2+ dependent 1KHD
FUT9ECFucosyltransferase 9HD
FAM189A2ECFamily with sequence similarity 189 member A2Neurodegenerative disease
ATG4CECAutophagy related 4C cysteine peptidaseNeurodegenerative disease
TSPAN6ECTetraspanin 6Neurodegenerative disease
SLC44A1ECSolute carrier family 44 member 1Neurodegenerative disease
SUMF1ECSulfatase modifying factor 1Neurodegenerative disease
AD and other neurodegenerative diseases associate genes identified from DEGs using GCBI online software. The down/up situation of 57 AD-associate genes identified in the meta-analysis in each individual dataset.

Analysis of the DEG PPI Network and Identification of Hub Nodes

The 207 DEGs were subjected to STRING v.11.0 to study the PPI network, and 154 nodes were sorted. The interaction network was then analyzed using the Network Analyzer tool (Shannon et al., 2003) (Figure 5). The 154 genes showed varying degrees of distribution, with a maximum degree of 39 and a minimum degree of 1. The upper eight nodes (top 5% of all nodes) with high degree and high closeness centrality values were chosen as hub nodes (Table 6). These eight hubs (GAPDH, RPS27A, GFAP, B2M, CLU, EEF2, GJA1, and CP) have all previously been found to be involved in the process of AD (Deane et al., 2005; Li et al., 2005; Olah et al., 2011; El Kadmiri et al., 2014; Guerreiro et al., 2015; Kamphuis et al., 2015; Almeida et al., 2018; Karagkouni et al., 2018).
Figure 5

PPI network of the DEGs. Red, up-regulation; green, down-regulation.

Table 6

The hub genes identified from the meta-analysis DEGs.

Gene symbolsDegreeClosenessCentralityMeta.expressionMeta. QpvalMeta. pvalBrain tissue
GAPDH390.47727273−0.5431329060.9030405830.011108607EC
RPS27A250.42241379−0.5063899680.5018318080.00902696HIP
B2M130.38786280.3530230460.5798302310.040853160EC
GFAP160.385826770.3980187350.3534846530.013506136EC
EEF2140.38281250.3867967080.3586800340.043927779MTG
CP100.385826770.5233513290.9189432590.0137236EC
CLU120.384816750.4477789710.4487858480.01315427EC
GJA1100.38281250.2522285680.6743050990.045547895HIP
PPI network of the DEGs. Red, up-regulation; green, down-regulation. The hub genes identified from the meta-analysis DEGs.

The miRNAs Associated With the AD-Associated and Other Neurodegenerative Disease-Associated DEGs, and the lncRNAs Associated With These miRNAs

To investigate the interactions between the AD-associated DEGs and non-coding RNAs, miRNAs associated with these genes were analyzed using the DIANA-Tarbase v.8.0 database. Of these miRNAs, 48 miRNAs were related to AD (Table 7), and 22 miRNAs were associated with other neurodegenerative diseases, such as multiple sclerosis and Parkinson's disease (Table 8). To investigate the interactions between the other neurodegenerative disease-associated DEGs and non-coding RNAs, 17 miRNAs were identified as being related to AD (Table 9). Moreover, most of these miRNAs were in turn regulated by many lncRNAs.
Table 7

AD-associate miRNAs associated with the AD-associate DEGs.

AD-associate DEGsAD-associate miRNAs associated with geneslncRNAs associated with miRNAs
ADAP1 (downregulated)hsa-miR-21-3pXLOC_013174
hsa-miR-27a-5p
BRSK2 (downregulated)hsa-miR-27a-3pC1orf132;DLX6-AS1;FLJ37201;IPW;KCNA3;KCNQ1OT1;LINC00548;LINC00662;LOC283070;MIR4534;NEAT1;RASSF8-AS1;RP11-111K18.2;RP11-129M16.4;RP11-175O19.4;RP11-196G18.22;RP11-314B1.2;RP11-361F15.2;RP11-553L6.5;RP11-94L15.2;RP13-735L24.1;RPA3-AS1;SNHG14;TMX2-CTNND1;TOB1-AS1;XLOC_003240;XLOC_008152;XLOC_010463;XLOC_011185;XLOC_013093;XXbac-BPGBPG55C20.2
DMTN (downregulated)hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-27a-3pC1orf132;DLX6-AS1;FLJ37201;IPW;KCNA3;KCNQ1OT1;LINC00548;LINC00662;LOC283070;MIR4534;NEAT1;RASSF8-AS1;RP11-111K18.2;RP11-129M16.4;RP11-175O19.4;RP11-196G18.22;RP11-314B1.2;RP11-361F15.2;RP11-553L6.5;RP11-94L15.2;RP13-735L24.1;RPA3-AS1;SNHG14;TMX2-CTNND1;TOB1-AS1;XLOC_003240;XLOC_008152;XLOC_010463;XLOC_011185;XLOC_013093;XXbac-BPGBPG55C20.2
DNM1 (downregulated)hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-128-3p
hsa-miR-27a-3pC1orf132;DLX6-AS1;FLJ37201;IPW;KCNA3;KCNQ1OT1;LINC00548;LINC00662;LOC283070;MIR4534;NEAT1;RASSF8-AS1;RP11-111K18.2;RP11-129M16.4;RP11-175O19.4;RP11-196G18.22;RP11-314B1.2;RP11-361F15.2;RP11-553L6.5;RP11-94L15.2;RP13-735L24.1;RPA3-AS1;SNHG14;TMX2-CTNND1;TOB1-AS1;XLOC_003240;XLOC_008152;XLOC_010463;XLOC_011185;XLOC_013093;XXbac-BPGBPG55C20.2
hsa-miR-9-5pCTB-89H12.4;KCNQ1OT1;RP11-273G15.2;RP11-793H13.8;SNHG14;TSNAX-DISC1;TUG1;XLOC_013093
GNAS (downregulated)hsa-miR-182-5pHOXA10-HOXA9;KCNQ1OT1;PCAT19;RP1-309I22.2
hsa-miR-424-5pAC005540.3;C1orf132;C1RL-AS1;INO80B-WBP1;KCNQ1OT1;LINC00662;MIA-RAB4B;RP11-379I19.1;RP1-309I22.2;RP5-991G20.1;RP6-24A23.7;XIST;XLOC_006753;XLOC_008207
GNB5 (downregulated)hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-148b-3pCASC7;OIP5-AS1;SLMO2-ATP5E;SNHG14
hsa-miR-503-5p
HCFC1R1 (downregulated)hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-23b-3pCASC7;CTC-459F4.3;KCNQ1OT1;NEAT1;RP11-159G9.5;RP11-215G15.5;SNHG14;TOB1-AS1;XIST;XLOC_005784;ZNRD1-AS1
hsa-miR-27a-5p
HSPBP1 (downregulated)hsa-miR-27a-3pC1orf132;DLX6-AS1;FLJ37201;IPW;KCNA3;KCNQ1OT1;LINC00548;LINC00662;LOC283070;MIR4534;NEAT1;RASSF8-AS1;RP11-111K18.2;RP11-129M16.4;RP11-175O19.4;RP11-196G18.22;RP11-314B1.2;RP11-361F15.2;RP11-553L6.5;RP11-94L15.2;RP13-735L24.1;RPA3-AS1;SNHG14;TMX2-CTNND1;TOB1-AS1;XLOC_003240;XLOC_008152;XLOC_010463;XLOC_011185;XLOC_013093;XXbac-BPGBPG55C20.2
INA (downregulated)hsa-let-7b-5pAP001055.6;BACE1-AS;CASC7;HOXA10-HOXA9;KCNQ1OT1;NEAT1;RP11-23J9.4;RP11-391M1.4;RP11-438B23.2;RP11-834C11.4;RP11-923I11.8;ST3GAL5-AS1;TRG-AS1;TUG1;XIST;XLOC_000647
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;LINC00662;RP11-359B12.2;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
L1CAM (downregulated)hsa-let-7b-5pAP001055.6;BACE1-AS;CASC7;HOXA10-HOXA9;KCNQ1OT1;NEAT1;RP11-23J9.4;RP11-391M1.4;RP11-438B23.2;RP11-834C11.4;RP11-923I11.8;ST3GAL5-AS1;TRG-AS1;TUG1;XIST;XLOC_000647
hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;LINC00662;RP11-359B12.2;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-182-5pHOXA10-HOXA9;KCNQ1OT1;PCAT19;RP1-309I22.2
hsa-miR-195-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-361F15.2;RP11-96D1.10;RP5-991G20.1;RP6-24A23.7;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-375KCNQ1OT1;SNHG14;SNORD116-20
MLST8 (downregulated)hsa-let-7b-5pAP001055.6;BACE1-AS;CASC7;HOXA10-HOXA9;KCNQ1OT1;NEAT1;RP11-23J9.4;RP11-391M1.4;RP11-438B23.2;RP11-834C11.4;RP11-923I11.8;ST3GAL5-AS1;TRG-AS1;TUG1;XIST;XLOC_000647
hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-130a-3pCASC7;H19;SNHG14
hsa-miR-200b-3pCTC-444N24.11;XIST;XLOC_013174
NDUFV3 (downregulated)hsa-let-7a-5pAP001055.6;BACE1-AS;CASC7;HOXA10-HOXA9;KCNQ1OT1;MEG3;NEAT1;RP11-391M1.4;RP11-438B23.2;RP11-834C11.4;RP11-923I11.8;ST3GAL5-AS1;TRG-AS1;TUG1;XIST;XLOC_008829;XLOC_010445;XLOC_013274;ZNRD1-AS1
hsa-let-7b-5pAP001055.6;BACE1-AS;CASC7;HOXA10-HOXA9;KCNQ1OT1;NEAT1;RP11-23J9.4;RP11-391M1.4;RP11-438B23.2;RP11-834C11.4;RP11-923I11.8;ST3GAL5-AS1;TRG-AS1;TUG1;XIST;XLOC_000647
hsa-let-7c-5pCASC7;TRG-AS1;XIST;XLOC_010445
NRGN (downregulated)hsa-miR-107CASC7;KCNQ1OT1;LINC00662;MIR4534;RP11-361F15.2;RP6-24A23.7;STAG3L5P-PVRIG2P-PILRB;XLOC_006753
hsa-miR-195-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-361F15.2;RP11-96D1.10;RP5-991G20.1;RP6-24A23.7;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-26a-5pCTD-3064H18.1;DLX6-AS1;GAS5;GS1-124K5.3;KCNQ1OT1;MIR181A1HG;RP11-1006G14.4;RP11-119F7.5;RP11-120E11.2;RP11-1C8.7;RP11-282O18.3;RP11-305E6.4;RP11-78O7.2;RP4-635E18.8;RP5-1172N10.4;THUMPD3-AS1;TUG1;VSTM2A-OT1;XLOC_001148;XLOC_002746;XLOC_013174
PCSK1N (downregulated)hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
RAD23A (downregulated)hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-200b-3pCTC-444N24.11;XIST;XLOC_013174
RPH3A (downregulated)hsa-miR-27a-3pC1orf132;DLX6-AS1;FLJ37201;IPW;KCNA3;KCNQ1OT1;LINC00548;LINC00662;LOC283070;MIR4534;NEAT1;RASSF8-AS1;RP11-111K18.2;RP11-129M16.4;RP11-175O19.4;RP11-196G18.22;RP11-314B1.2;RP11-361F15.2;RP11-553L6.5;RP11-94L15.2;RP13-735L24.1;RPA3-AS1;SNHG14;TMX2-CTNND1;TOB1-AS1;XLOC_003240;XLOC_008152;XLOC_010463;XLOC_011185;XLOC_013093;XXbac-BPGBPG55C20.2
RPS27A (downregulated)hsa-miR-181a-5pAC000403.4;CASC7;CTB-89H12.4;IPW;KCNIP4-IT1;KCNQ1OT1;LINC00506;N4BP2L2-IT2;RP11-10E18.7;RP11-1134I14.8;RP11-147L13.14;RP11-314B1.2;RP11-361F15.2;RP11-707A18.1;RP1-309I22.2;XLOC_003971;XLOC_010463;XLOC_011185;ZNF883;ZNRD1-AS1
SLC17A6 (downregulated)hsa-miR-27a-3pC1orf132;DLX6-AS1;FLJ37201;IPW;KCNA3;KCNQ1OT1;LINC00548;LINC00662;LOC283070;MIR4534;NEAT1;RASSF8-AS1;RP11-111K18.2;RP11-129M16.4;RP11-175O19.4;RP11-196G18.22;RP11-314B1.2;RP11-361F15.2;RP11-553L6.5;RP11-94L15.2;RP13-735L24.1;RPA3-AS1;SNHG14;TMX2-CTNND1;TOB1-AS1;XLOC_003240;XLOC_008152;XLOC_010463;XLOC_011185;XLOC_013093;XXbac-BPGBPG55C20.2
TOMM40 (downregulated)hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
TUBB4B (downregulated)hsa-let-7b-5pAP001055.6;BACE1-AS;CASC7;HOXA10-HOXA9;KCNQ1OT1;NEAT1;RP11-23J9.4;RP11-391M1.4;RP11-438B23.2;RP11-834C11.4;RP11-923I11.8;ST3GAL5-AS1;TRG-AS1;TUG1;XIST;XLOC_000647
hsa-miR-128-3p
hsa-miR-148b-3pCASC7;CTD-2303H24.2;OIP5-AS1;SLMO2-ATP5E;SNHG14
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-17-5pAC006548.28;CTB-89H12.4;CTD-2015H6.3;GABPB1-AS1;HCG11;LINC00657;MIR6080;MIR8072;PWAR6;PWARSN;RP11-162A12.4;RP11-171I2.1;RP11-361F15.2;RP11-363E7.4;RP11-399O19.9;RP11-553L6.5;RP11-81A1.6;RP11-909M7.3;XLOC_011677
hsa-miR-18a-5pAC000403.4;CASC7;CTB-89H12.4;IPW;KCNIP4-IT1;KCNQ1OT1;LINC00506;N4BP2L2-IT2;RP11-10E18.7;RP11-1134I14.8;RP11-147L13.14;RP11-314B1.2;RP11-361F15.2;RP11-707A18.1;RP1-309I22.2;XLOC_003971;XLOC_010463;XLOC_011185;ZNF883;ZNRD1-AS1
hsa-miR-18b-5pXIST;XLOC_014102
hsa-miR-23a-3pCASC7;KCNQ1OT1;NEAT1;RP11-159G9.5;RP11-215G15.5;SNHG14;TOB1-AS1;XIST;ZNRD1-AS1
hsa-miR-23b-3pCASC7;CTC-459F4.3;KCNQ1OT1;NEAT1;RP11-159G9.5;RP11-215G15.5;SNHG14;TOB1-AS1;XIST;XLOC_005784;ZNRD1-AS1
hsa-miR-27b-3pC1orf132;DLX6-AS1;FLJ37201;IPW;KCNA3;KCNQ1OT1;LINC00548;LINC00662;LOC283070;NEAT1;RASSF8-AS1;RP11-111K18.2;RP11-129M16.4;RP11-175O19.4;RP11-196G18.22;RP11-314B1.2;RP11-553L6.5;RP11-94L15.2;RP13-735L24.1;RPA3-AS1;SNHG14;
ADAP2 (upregulated)hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-29c-3pAC005154.6;AC006548.28;H19;KCNQ1OT1;LINC00674;MIR4697HG;NEAT1;RP11-314B1.2;RP11-582E3.6;RP4-630A11.3;THUMPD3-AS1;TTTY15;TUG1;XLOC_004366;XLOC_007942;XLOC_008295
hsa-let-7b-5pAP001055.6;BACE1-AS;CASC7;HOXA10-HOXA9;KCNQ1OT1;NEAT1;RP11-23J9.4;RP11-391M1.4;RP11-438B23.2;RP11-834C11.4;RP11-923I11.8;ST3GAL5-AS1;TRG-AS1;TUG1;XIST;XLOC_000647
hsa-miR-101-3pAC005235.1;CTD-2303H24.2;CTD-2571L23.8;FAM201A;HCG11;KCNQ1OT1;LINC00657;LINC00662;LINC00936;RP11-102L12.2;RP11-1134I14.8;RP11-196G18.24;RP11-350F4.2;RP11-378J18.8;RP11-421E14.2;XIST;XLOC_002872
APBB1IP (upregulated)hsa-miR-27a-3pC1orf132;DLX6-AS1;FLJ37201;IPW;KCNA3;KCNQ1OT1;LINC00548;LINC00662;LOC283070;MIR4534;NEAT1;RASSF8-AS1;RP11-111K18.2;RP11-129M16.4;RP11-175O19.4;RP11-196G18.22;RP11-314B1.2;RP11-361F15.2;RP11-553L6.5;RP11-94L15.2;RP13-735L24.1;RPA3-AS1;SNHG14;TMX2-CTNND1;TOB1-AS1;XLOC_003240;XLOC_008152;XLOC_010463;XLOC_011185;XLOC_013093;XXbac-BPGBPG55C20.2
ARFGAP3 (upregulated)hsa-miR-200b-3pCTC-444N24.11;XIST;XLOC_013174
ATRAID (upregulated)hsa-miR-23b-3pCASC7;CTC-459F4.3;KCNQ1OT1;NEAT1;RP11-159G9.5;RP11-215G15.5;SNHG14;TOB1-AS1;XIST;XLOC_005784;ZNRD1-AS1
hsa-let-7b-5pAP001055.6;BACE1-AS;CASC7;HOXA10-HOXA9;KCNQ1OT1;NEAT1;RP11-23J9.4;RP11-391M1.4;RP11-438B23.2;RP11-834C11.4;RP11-923I11.8;ST3GAL5-AS1;TRG-AS1;TUG1;XIST;XLOC_000647
hsa-miR-101-3pAC005235.1;CTD-2303H24.2;CTD-2571L23.8;FAM201A;HCG11;KCNQ1OT1;LINC00657;LINC00662;LINC00936;RP11-102L12.2;RP11-1134I14.8;RP11-196G18.24;RP11-350F4.2;RP11-378J18.8;RP11-421E14.2;XIST;XLOC_002872
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
CAPN2 (upregulated)hsa-miR-101-3pAC005235.1;CTD-2303H24.2;CTD-2571L23.8;FAM201A;HCG11;KCNQ1OT1;LINC00657;LINC00662;LINC00936;RP11-102L12.2;RP11-1134I14.8;RP11-196G18.24;RP11-350F4.2;RP11-378J18.8;RP11-421E14.2;XIST;XLOC_002872
hsa-miR-148b-3pCASC7;CTD-2303H24.2;OIP5-AS1;SLMO2-ATP5E;SNHG14
hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-101-3pAC005235.1;CTD-2303H24.2;CTD-2571L23.8;FAM201A;HCG11;KCNQ1OT1;LINC00657;LINC00662;LINC00936;RP11-102L12.2;RP11-1134I14.8;RP11-196G18.24;RP11-350F4.2;RP11-378J18.8;RP11-421E14.2;XIST;XLOC_002872
CP (upregulated)hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-182-5pHOXA10-HOXA9;KCNQ1OT1;PCAT19;RP1-309I22.2
DYNLT1 (upregulated)hsa-miR-23b-3pCASC7;CTC-459F4.3;KCNQ1OT1;NEAT1;RP11-159G9.5;RP11-215G15.5;SNHG14;TOB1-AS1;XIST;XLOC_005784;ZNRD1-AS1
hsa-miR-128-3p
hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
GFAP (upregulated)hsa-miR-107CASC7;KCNQ1OT1;LINC00662;MIR4534;RP11-361F15.2;RP6-24A23.7;STAG3L5P-PVRIG2P-PILRB;XLOC_006753
hsa-miR-497-5pAC005540.3;C1orf132;C1RL-AS1;FGF14-IT1;GS1-358P8.4;INO80B-WBP1;KCNQ1OT1;LINC00662;MIA-RAB4B;RP11-361F15.2;RP5-991G20.1;RP6-24A23.7;XIST;XLOC_006753;XLOC_008207;XLOC_013174;XLOC_013424
hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-15a-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;MCM3AP-AS1;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP5-991G20.1;RP6-24A23.7;XLOC_003546;XLOC_008207;XLOC_006753;XLOC_013174
hsa-miR-15b-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_008207;XLOC_013174
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-195-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-361F15.2;RP11-96D1.10;RP5-991G20.1;RP6-24A23.7;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-24-3pCTA-292E10.9;CTC-273B12.8;GABPB1-AS1;LINC00662;LOC388692;MIR4534;RP11-54O7.1;XLOC_006242;XLOC_008461;XLOC_011313
HSPB8 (upregulated)hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-let-7b-5pAP001055.6;BACE1-AS;CASC7;HOXA10-HOXA9;KCNQ1OT1;NEAT1;RP11-23J9.4;RP11-391M1.4;RP11-438B23.2;RP11-834C11.4;RP11-923I11.8;ST3GAL5-AS1;TRG-AS1;TUG1;XIST;XLOC_000647
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-133a-3p
IQCK (upregulated)hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-107CASC7;KCNQ1OT1;LINC00662;MIR4534;RP11-361F15.2;RP6-24A23.7;STAG3L5P-PVRIG2P-PILRB;XLOC_006753
LAP3 (upregulated)hsa-miR-495-3p
hsa-miR-503-5p
hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-128-3p
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-21-3pXLOC_013174
hsa-miR-27a-5p
hsa-miR-133a-3p
MAN2A1 (upregulated)hsa-miR-27a-3pC1orf132;DLX6-AS1;FLJ37201;IPW;KCNA3;KCNQ1OT1;LINC00548;LINC00662;LOC283070;MIR4534;NEAT1;RASSF8-AS1;RP11-111K18.2;RP11-129M16.4;RP11-175O19.4;RP11-196G18.22;RP11-314B1.2;RP11-361F15.2;RP11-553L6.5;RP11-94L15.2;RP13-735L24.1;RPA3-AS1;SNHG14;TMX2-CTNND1;TOB1-AS1;XLOC_003240;XLOC_008152;XLOC_010463;XLOC_011185;XLOC_013093;XXbac-BPGBPG55C20.2
hsa-miR-27b-3pC1orf132;DLX6-AS1;FLJ37201;IPW;KCNA3;KCNQ1OT1;LINC00548;LINC00662;LOC283070;NEAT1;RASSF8-AS1;RP11-111K18.2;RP11-129M16.4;RP11-175O19.4;RP11-196G18.22;RP11-314B1.2;RP11-553L6.5;RP11-94L15.2;RP13-735L24.1;RPA3-AS1;SNHG14
hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-let-7b-5pAP001055.6;BACE1-AS;CASC7;HOXA10-HOXA9;KCNQ1OT1;NEAT1;RP11-23J9.4;RP11-391M1.4;RP11-438B23.2;RP11-834C11.4;RP11-923I11.8;ST3GAL5-AS1;TRG-AS1;TUG1;XIST;XLOC_000647
hsa-miR-182-5pHOXA10-HOXA9;KCNQ1OT1;PCAT19;RP1-309I22.2
MEGF10 (upregulated)hsa-miR-26a-5pCTD-3064H18.1;DLX6-AS1;GAS5;GS1-124K5.3;KCNQ1OT1;MIR181A1HG;RP11-1006G14.4;RP11-119F7.5;RP11-120E11.2;RP11-1C8.7;RP11-282O18.3;RP11-305E6.4;RP11-78O7.2;RP4-635E18.8;RP5-1172N10.4;THUMPD3-AS1;TUG1;VSTM2A-OT1;XLOC_001148;XLOC_002746;XLOC_013174
hsa-miR-101-3pAC005235.1;CTD-2303H24.2;CTD-2571L23.8;FAM201A;HCG11;KCNQ1OT1;LINC00657;LINC00662;LINC00936;RP11-102L12.2;RP11-1134I14.8;RP11-196G18.24;RP11-350F4.2;RP11-378J18.8;RP11-421E14.2;XIST;XLOC_002872
hsa-miR-182-5pHOXA10-HOXA9;KCNQ1OT1;PCAT19;RP1-309I22.2
MT1M (upregulated)hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-21-3pXLOC_013174
hsa-miR-27a-3pC1orf132;DLX6-AS1;FLJ37201;IPW;KCNA3;KCNQ1OT1;LINC00548;LINC00662;LOC283070;MIR4534;NEAT1;RASSF8-AS1;RP11-111K18.2;RP11-129M16.4;RP11-175O19.4;RP11-196G18.22;RP11-314B1.2;RP11-361F15.2;RP11-553L6.5;RP11-94L15.2;RP13-735L24.1;RPA3-AS1;SNHG14;TMX2-CTNND1;TOB1-AS1;XLOC_003240;XLOC_008152;XLOC_010463;XLOC_011185;XLOC_013093;XXbac-BPGBPG55C20.2
hsa-miR-27a-5p
hsa-miR-376a-5pKCNQ1OT1;SIK3-IT1
MT3 (upregulated)hsa-let-7b-5pAP001055.6;BACE1-AS;CASC7;HOXA10-HOXA9;KCNQ1OT1;NEAT1;RP11-23J9.4;RP11-391M1.4;RP11-438B23.2;RP11-834C11.4;RP11-923I11.8;ST3GAL5-AS1;TRG-AS1;TUG1;XIST;XLOC_000647
hsa-miR-182-5pHOXA10-HOXA9;KCNQ1OT1;PCAT19;RP1-309I22.2
NPL (upregulated)hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-27a-5p
PCSK1N (upregulated)hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
PLXDC2 (upregulated)hsa-miR-29a-3pAC005154.6;AC006548.28;H19;KCNQ1OT1;LINC00674;MIR4697HG;NEAT1;RP11-314B1.2;RP11-582E3.6;RP4-630A11.3;THUMPD3-AS1;TTTY15;TUG1;XLOC_004366;XLOC_007942;XLOC_008295
hsa-miR-29b-3pAC005154.6;AC006548.28;H19;KCNQ1OT1;LINC00674;MIR4697HG;NEAT1;RP11-314B1.2;RP11-582E3.6;RP4-630A11.3;THUMPD3-AS1;TTTY15;TUG1;XLOC_004366;XLOC_007942;XLOC_008295
hsa-miR-29c-3pAC005154.6;AC006548.28;H19;KCNQ1OT1;LINC00674;MIR4697HG;NEAT1;RP11-314B1.2;RP11-582E3.6;RP4-630A11.3;THUMPD3-AS1;TTTY15;TUG1;XLOC_004366;XLOC_007942;XLOC_008295
hsa-miR-27a-3pAC005154.6;AC006548.28;H19;KCNQ1OT1;LINC00674;MIR4697HG;NEAT1;RP11-314B1.2;RP11-582E3.6;RP4-630A11.3;THUMPD3-AS1;TTTY15;TUG1;XLOC_004366;XLOC_007942;XLOC_008295
PRDX1 (upregulated)hsa-miR-29a-3pAC005154.6;AC006548.28;H19;KCNQ1OT1;LINC00674;MIR4697HG;NEAT1;RP11-314B1.2;RP11-582E3.6;RP4-630A11.3;THUMPD3-AS1;TTTY15;TUG1;XLOC_004366;XLOC_007942;XLOC_008295
hsa-miR-23b-3pCASC7;CTC-459F4.3;KCNQ1OT1;NEAT1;RP11-159G9.5;RP11-215G15.5;SNHG14;TOB1-AS1;XIST;XLOC_005784;ZNRD1-AS1
hsa-miR-375KCNQ1OT1;SNHG14;SNORD116-20
PRDX6 (upregulated)hsa-miR-23b-3pCASC7;CTC-459F4.3;KCNQ1OT1;NEAT1;RP11-159G9.5;RP11-215G15.5;SNHG14;TOB1-AS1;XIST;XLOC_005784;ZNRD1-AS1
hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-133a-3p
RAB10 (upregulated)hsa-miR-130b-3pCASC7;H19;SNHG14
hsa-miR-148b-3pCASC7;CTD-2303H24.2;OIP5-AS1;SLMO2-ATP5E;SNHG14
hsa-miR-107CASC7;KCNQ1OT1;LINC00662;MIR4534;RP11-361F15.2;RP6-24A23.7;STAG3L5P-PVRIG2P-PILRB;XLOC_006753
hsa-miR-16-5p;AC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-15a-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;MCM3AP-AS1;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP5-991G20.1;RP6-24A23.7;XLOC_003546;XLOC_008207;XLOC_006753;XLOC_013174
hsa-miR-15b-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_008207;XLOC_013174
hsa-miR-143-3pAC090587.2;CTB-193M12.3;EEF1E1-BLOC1S5;FLJ31306;GABPB1-AS1;KCNQ1OT1;LINC00662;MESTIT1;OIP5-AS1;PDCD4-AS1;RP11-424G14.1;RP5-1014D13.2
hsa-miR-30b-5pAC096772.6;CASC7;CTA-292E10.9;CTB-89H12.4;HCG18;LINC00461;LOC100128288;MIA-RAB4B;OIP5-AS1;PWRN3;RP11-175O19.4;RP11-265E18.1;RP11-361F15.2;RP11-378J18.8;RP11-618G20.1;RP11-731J8.2;RP1-309I22.2;RP6-24A23.7;TRHDE-AS1;UG0898H09;XIST;XLOC_005753;XLOC_008207
hsa-miR-30c-5pAC096772.6;CASC7;CTA-292E10.9;CTB-89H12.4;LINC00461;LOC100128288;MIA-RAB4B;PWRN3;RP11-175O19.4;RP11-265E18.1;RP11-361F15.2;RP11-618G20.1;RP11-731J8.2;RP1-309I22.2;UG0898H09;XIST;XLOC_005753;XLOC_008207
hsa-miR-195-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-361F15.2;RP11-96D1.10;RP5-991G20.1;RP6-24A23.7;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-23a-3pCASC7;KCNQ1OT1;NEAT1;RP11-159G9.5;RP11-215G15.5;SNHG14;TOB1-AS1;XIST;ZNRD1-AS1
hsa-miR-23b-3pCASC7;CTC-459F4.3;KCNQ1OT1;NEAT1;RP11-159G9.5;RP11-215G15.5;SNHG14;TOB1-AS1;XIST;XLOC_005784;ZNRD1-AS1
hsa-miR-497-5pAC005540.3;C1orf132;C1RL-AS1;FGF14-IT1;GS1-358P8.4;INO80B-WBP1;KCNQ1OT1;LINC00662;MIA-RAB4B;RP11-361F15.2;RP5-991G20.1;RP6-24A23.7;XIST;XLOC_006753;XLOC_008207;XLOC_013174;XLOC_013424
SEPP1 (upregulated)hsa-miR-20a-5pAC006548.28;CTB-89H12.4;LINC00116;GABPB1-AS1;RP11-553L6.5;RP11-81A1.6;SNORD109A;XIST;XLOC_002263;XLOC_004804;XLOC_013093
hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-let-7b-5pAP001055.6;BACE1-AS;CASC7;HOXA10-HOXA9;KCNQ1OT1;NEAT1;RP11-23J9.4;RP11-391M1.4;RP11-438B23.2;RP11-834C11.4;RP11-923I11.8;ST3GAL5-AS1;TRG-AS1;TUG1;XIST;XLOC_000647
hsa-miR-101-3pAC005235.1;CTD-2303H24.2;CTD-2571L23.8;FAM201A;HCG11;KCNQ1OT1;LINC00657;LINC00662;LINC00936;RP11-102L12.2;RP11-1134I14.8;RP11-196G18.24;RP11-350F4.2;RP11-378J18.8;RP11-421E14.2;XIST;XLOC_002872
hsa-miR-128-3p
hsa-miR-26a-5pCTD-3064H18.1;DLX6-AS1;GAS5;GS1-124K5.3;KCNQ1OT1;MIR181A1HG;RP11-1006G14.4;RP11-119F7.5;RP11-120E11.2;RP11-1C8.7;RP11-282O18.3;RP11-305E6.4;RP11-78O7.2;RP4-635E18.8;RP5-1172N10.4;THUMPD3-AS1;TUG1;VSTM2A-OT1;XLOC_001148;XLOC_002746;XLOC_013174
SERPINA3 (upregulated)hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
hsa-miR-20a-5pAC006548.28;CTB-89H12.4;LINC00116;GABPB1-AS1;RP11-553L6.5;RP11-81A1.6;SNORD109A;XIST;XLOC_002263;XLOC_004804;XLOC_013093
hsa-miR-30d-5pCASC7;CTA-292E10.9;CTB-89H12.4;HCG18;LINC00461;LOC100128288;RP11-175O19.4;RP11-361F15.2;RP11-618G20.1;RP1-309I22.2;RP6-24A23.7;XIST;XLOC_008207
hsa-miR-130a-3pCASC7;H19;SNHG14
hsa-miR-182-5pHOXA10-HOXA9;KCNQ1OT1;PCAT19;RP1-309I22.2
hsa-miR-27a-3pAC005154.6;AC006548.28;H19;KCNQ1OT1;LINC00674;MIR4697HG;NEAT1;RP11-314B1.2;RP11-582E3.6;RP4-630A11.3;THUMPD3-AS1;TTTY15;TUG1;XLOC_004366;XLOC_007942;XLOC_008295
SLC16A9 (upregulated)hsa-miR-424-5pAC005540.3;C1orf132;C1RL-AS1;INO80B-WBP1;KCNQ1OT1;LINC00662;MIA-RAB4B;RP11-379I19.1;RP1-309I22.2;RP5-991G20.1;RP6-24A23.7;XIST;XLOC_006753;XLOC_008207;
hsa-miR-9-3pALMS1-IT1;ALMS1-IT1;RP11-175O19.4;RP11-438B23.2;RP4-714D9.5;TTN-AS1;XIST;XLOC_002872;XLOC_010463
hsa-miR-101-3pAC005235.1;CTD-2303H24.2;CTD-2571L23.8;FAM201A;HCG11;KCNQ1OT1;LINC00657;LINC00662;LINC00936;RP11-102L12.2;RP11-1134I14.8;RP11-196G18.24;RP11-350F4.2;RP11-378J18.8;RP11-421E14.2;XIST;XLOC_002872
hsa-miR-21-3pXLOC_013174
hsa-miR-27a-5p
hsa-miR-29c-3pAC005154.6;AC006548.28;H19;KCNQ1OT1;LINC00674;MIR4697HG;NEAT1;RP11-314B1.2;RP11-582E3.6;RP4-630A11.3;THUMPD3-AS1;TTTY15;TUG1;XLOC_004366;XLOC_007942;XLOC_008295
SRSF6 (upregulated)hsa-miR-26a-5pCTD-3064H18.1;DLX6-AS1;GAS5;GS1-124K5.3;HOXA10-HOXA9;MIR181A1HG;MIR6080;RP11-1006G14.4;RP11-119F7.5;RP11-120E11.2;RP11-1C8.7;RP11-282O18.3;RP11-305E6.4;RP11-78O7.2;RP4-635E18.8;RP5-1172N10.4;THUMPD3-AS1;VSTM2A-OT1;XLOC_001148;XLOC_002746;XLOC_013174
hsa-miR-93-5pAC006548.28;CTB-89H12.4;CTD-2015H6.3;GABPB1-AS1;HCG11;LINC00657;MIR6080;MIR8072;PWAR6;PWARSN;RP11-162A12.4;RP11-361F15.2;RP11-363E7.4;RP11-399O19.9;RP11-553L6.5;RP11-909M7.3;XLOC_004804;XLOC_010706;XLOC_011677
hsa-miR-340-5pAC002429.5;CASC7;CTC-444N24.11;LINC00662;LINC01355;NEAT1;RP11-119F7.5;RP11-174G6.5;RP11-96D1.10;TUG1;XIST;XLOC_002282;XLOC_008207
hsa-miR-137CASC7;CTB-89H12.4;CTC-459F4.3;HCG18;KB-1410C5.5;OIP5-AS1;RP11-314B1.2;RP11-498C9.15;RP11-78O7.2;SNHG14;XLOC_004457
hsa-miR-101-3pAC005235.1;CTD-2303H24.2;CTD-2571L23.8;FAM201A;HCG11;KCNQ1OT1;LINC00657;LINC00662;LINC00936;RP11-102L12.2;RP11-1134I14.8;RP11-196G18.24;RP11-350F4.2;RP11-378J18.8;RP11-421E14.2;XIST;XLOC_002872
hsa-miR-27a-3pAC005154.6;AC006548.28;H19;KCNQ1OT1;LINC00674;MIR4697HG;NEAT1;RP11-314B1.2;RP11-582E3.6;RP4-630A11.3;THUMPD3-AS1;TTTY15;TUG1;XLOC_004366;XLOC_007942;XLOC_008295
hsa-miR-27b-3pC1orf132;DLX6-AS1;FLJ37201;IPW;KCNA3;KCNQ1OT1;LINC00548;LINC00662;LOC283070;NEAT1;RASSF8-AS1;RP11-111K18.2;RP11-129M16.4;RP11-175O19.4;RP11-196G18.22;RP11-314B1.2;RP11-553L6.5;RP11-94L15.2;RP13-735L24.1;RPA3-AS1;SNHG14;
hsa-miR-124-3pAL022344.7;ERVK13-1;KCNQ1OT1;LINC00643;LOC284581;NEAT1;RAD51L3-RFFL;RP11-508N22.12;RP11-731J8.2;RP11-74E22.8;TMEM256-PLSCR3;TTTY15;XLOC_006753;XLOC_010853;XLOC_013174;XLOC_013844
WDR11 (upregulated)hsa-miR-26b-5pGAS5;GS1-124K5.3;HOXA10-HOXA9;RP11-119F7.5;RP11-120E11.2;THUMPD3-AS1;TUG1;XLOC_013174
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-182-5pHOXA10-HOXA9;KCNQ1OT1;PCAT19;RP1-309I22.2
GJA1 (upregulated)hsa-miR-107CASC7;KCNQ1OT1;LINC00662;MIR4534;RP11-361F15.2;RP6-24A23.7;STAG3L5P-PVRIG2P-PILRB;XLOC_006753
Table 8

Other neurodegenerative disease-specific miRNAs associated with the AD-associate DEGs.

AD-associate DEGsOther neurodegenerative disease-specific miRNAs associated with geneslncRNAs associated with miRNAs
DMTN (downregulated)hsa-miR-34a-5pAC004951.6;AC092535.3;KCNQ1OT1;LINC00662;MIR4534;PCBP2-OT1;RP11-693J15.5
hsa-miR-7-5pAC005154.6;DLX6-AS1;KCNQ1OT1;LINC01233;LINC01314;MIR4534;OIP5-AS1;OIP5-AS1;RP11-679B19.1;RP1-309I22.2;XIST
FXYD7 (downregulated)hsa-miR-212-3pCASC7;CTB-89H12.4;NEAT1;RP11-26J3.3;XIST;XLOC_006753
GAPDH (downregulated)hsa-miR-34a-5pAC004951.6;AC092535.3;KCNQ1OT1;LINC00662;MIR4534;PCBP2-OT1;RP11-693J15.5
HSPBP1 (downregulated)hsa-miR-194-5pCTB-89H12.4;KCNQ1OT1
hsa-miR-34a-5pAC004951.6;AC092535.3;KCNQ1OT1;LINC00662;MIR4534;PCBP2-OT1;RP11-693J15.5
hsa-miR-7-5pAC005154.6;DLX6-AS1;KCNQ1OT1;LINC01233;LINC01314;MIR4534;OIP5-AS1;OIP5-AS1;RP11-679B19.1;RP1-309I22.2;XIST
INA (downregulated)hsa-miR-212-3pCASC7;CTB-89H12.4;NEAT1;RP11-26J3.3;XIST;XLOC_006753
hsa-miR-34a-5pAC004951.6;AC092535.3;KCNQ1OT1;LINC00662;MIR4534;PCBP2-OT1;RP11-693J15.5
MLST8 (downregulated)hsa-miR-7-5pAC005154.6;DLX6-AS1;KCNQ1OT1;LINC01233;LINC01314;MIR4534;OIP5-AS1;OIP5-AS1;RP11-679B19.1;RP1-309I22.2;XIST
NDUFV3 (downregulated)hsa-miR-374a-5pCTC-444N24.11;CTD-2561J22.5;RP11-613D13.5;TRG-AS1;XIST;XLOC_004545;XLOC_006322;ZNRD1-AS1
hsa-miR-494-3p
NRGN (downregulated)hsa-miR-34a-5pAC004951.6;AC092535.3;KCNQ1OT1;LINC00662;MIR4534;PCBP2-OT1;RP11-693J15.5
RPH3A (downregulated)hsa-miR-136-3pCTD-2140G10.2;KCNQ1OT1;LL22NC03-2H8.5;RP11-227G15.3;RP11-700J17.2;TTTY15;XLOC_008295
hsa-miR-221-3pAC000120.7;CTB-89H12.4;RP11-147L13.8
RPS27A (downregulated)hsa-miR-485-3pHCG11;LINC00657;RP11-482H16.1;RP11-95O2.1;RP3-445N2.1;XLOC_004244
SYN1 (downregulated)hsa-miR-302a-3pRP11-383H13.1
TOMM40 (downregulated)hsa-miR-194-5pCTB-89H12.4;KCNQ1OT1
TUBB4B (downregulated)hsa-miR-138-5pKCNQ1OT1;TSIX
hsa-miR-34a-5pAC004951.6;AC092535.3;KCNQ1OT1;LINC00662;MIR4534;PCBP2-OT1;RP11-693J15.5
hsa-miR-494-3p
ARFGAP3 (upregulated)hsa-miR-494-3p
CAPN2 (upregulated)hsa-miR-132-3pAPTR;CASC7;CTB-89H12.4;KCNIP4-IT1;KCNQ1OT1;NEAT1;RP11-26J3.3;XIST;XLOC_006753;YEATS2-AS1
hsa-miR-494-3p
hsa-miR-374a-5pCTC-444N24.11;CTD-2561J22.5;RP11-613D13.5;TRG-AS1;XIST;XLOC_004545;XLOC_006322;ZNRD1-AS1
CP (upregulated)hsa-miR-34a-5pAC004951.6;AC092535.3;KCNQ1OT1;LINC00662;MIR4534;PCBP2-OT1;RP11-693J15.5
hsa-miR-34b-5pKCNQ1OT1;RP11-458F8.4;TSIX;XIST
hsa-miR-34c-5pKCNQ1OT1;LINC01000;MIR4534
hsa-miR-449aKCNQ1OT1;MIR4534;XIST
hsa-miR-449b-5pKCNQ1OT1;MIR4534;XIST
DYNLT1 (upregulated)hsa-miR-34a-5pAC004951.6;AC092535.3;KCNQ1OT1;LINC00662;MIR4534;PCBP2-OT1;RP11-693J15.5
hsa-miR-449aKCNQ1OT1;MIR4534;XIST
GFAP (upregulated)hsa-miR-34a-5pAC004951.6;AC092535.3;KCNQ1OT1;LINC00662;MIR4534;PCBP2-OT1;RP11-693J15.5
HSPB8 (upregulated)hsa-miR-126-5pAC096772.6;C14orf23;C1QTNF3-AMACR;CH17-262A2.1;DLX6-AS1;FAM201A;KCNQ1OT1;LINC01004;LINC01420;LL22NC03-2H8.5;NEAT1;RP11-177G23.2;RP11-707A18.1;RP11-946L20.2;RP4-740C4.7;TTTY15;XLOC_001417;XLOC_003971;XLOC_005753;XLOC_008295;XLOC_010463
hsa-miR-485-5pCTA-342B11.3;GS1-124K5.11;KCNQ1OT1;MIR4534;RP11-266K22.2;RP11-504P24.8;RP11-658F2.8;RP1-309I22.2;RP5-1014D13.2;XLOC_013174;XLOC_013274
hsa-miR-494-3p
hsa-miR-374a-5pCTC-444N24.11;CTD-2561J22.5;RP11-613D13.5;TRG-AS1;XIST;XLOC_004545;XLOC_006322;ZNRD1-AS1
IQCK (upregulated)hsa-miR-7-5pAC005154.6;DLX6-AS1;KCNQ1OT1;LINC01233;LINC01314;MIR4534;OIP5-AS1;OIP5-AS1;RP11-679B19.1;RP1-309I22.2;XIST
LAP3 (upregulated)hsa-miR-494-3p
hsa-miR-449aKCNQ1OT1;MIR4534;XIST
hsa-miR-449b-5pKCNQ1OT1;MIR4534;XIST
MAN2A1 (upregulated)hsa-miR-7-5pAC005154.6;DLX6-AS1;KCNQ1OT1;LINC01233;LINC01314;MIR4534;OIP5-AS1;OIP5-AS1;RP11-679B19.1;RP1-309I22.2;XIST
hsa-miR-194-5pCTB-89H12.4;KCNQ1OT1
MT1M (upregulated)hsa-miR-374a-5pCTC-444N24.11;CTD-2561J22.5;RP11-613D13.5;TRG-AS1;XIST;XLOC_004545;XLOC_006322;ZNRD1-AS1
NPL (upregulated)hsa-miR-374a-5pCTC-444N24.11;CTD-2561J22.5;RP11-613D13.5;TRG-AS1;XIST;XLOC_004545;XLOC_006322;ZNRD1-AS1
PLXDC2 (upregulated)hsa-miR-7-5pAC005154.6;DLX6-AS1;KCNQ1OT1;LINC01233;LINC01314;MIR4534;OIP5-AS1;OIP5-AS1;RP11-679B19.1;RP1-309I22.2;XIST
hsa-miR-374a-5pCTC-444N24.11;CTD-2561J22.5;RP11-613D13.5;TRG-AS1;XIST;XLOC_004545;XLOC_006322;ZNRD1-AS1
PRDX1 (upregulated)hsa-miR-485-3pHCG11;LINC00657;RP11-482H16.1;RP11-95O2.1;RP3-445N2.1;XLOC_004244
hsa-miR-126-3p
hsa-miR-34a-5pAC004951.6;AC092535.3;KCNQ1OT1;LINC00662;MIR4534;PCBP2-OT1;RP11-693J15.5
PRDX6 (upregulated)hsa-miR-34a-5pAC004951.6;AC092535.3;KCNQ1OT1;LINC00662;MIR4534;PCBP2-OT1;RP11-693J15.5
RAB10 (upregulated)hsa-miR-19a-3pCASC7;FAM201A;H19;KCNA3;KCNQ1OT1;RP11-337C18.8;RP11-523G9.3;SNHG14
hsa-miR-19b-3pCASC7;FAM201A;H19;KCNA3;KCNQ1OT1;LINC00094;RP11-337C18.8;SNHG14
SEPP1 (upregulated)hsa-miR-218-5pDYX1C1-CCPG1;INO80B-WBP1;KCNQ1OT1;RP11-166D19.1;RP11-679B19.2;RP4-621B10.8;SNHG23;XLOC_004695;XLOC_010885
hsa-miR-194-5pCTB-89H12.4;KCNQ1OT1
hsa-miR-34b-5pKCNQ1OT1;RP11-458F8.4;TSIX;XIST
SERPINA3 (upregulated)hsa-miR-34a-5pAC004951.6;AC092535.3;KCNQ1OT1;LINC00662;MIR4534;PCBP2-OT1;RP11-693J15.5
hsa-miR-34c-5pKCNQ1OT1;LINC01000;MIR4534
hsa-miR-448
SLC16A9 (upregulated)hsa-miR-212-3pCASC7;CTB-89H12.4;NEAT1;RP11-26J3.3;XIST;XLOC_006753
hsa-miR-374a-5pCTC-444N24.11;CTD-2561J22.5;RP11-613D13.5;TRG-AS1;XIST;XLOC_004545;XLOC_006322;ZNRD1-AS1
SRSF6 (upregulated)hsa-miR-19a-3pCASC7;FAM201A;H19;KCNA3;KCNQ1OT1;RP11-337C18.8;RP11-523G9.3;SNHG14
hsa-miR-139-5pCTC-365E16.1;CTC-444N24.11;HOXA10-HOXA9;KCNQ1OT1;NR2F1-AS1;PWAR6;RMST;RP11-215G15.5;RP13-582O9.5;XLOC_009913
hsa-miR-494-3p
hsa-miR-34a-5pAC004951.6;AC092535.3;KCNQ1OT1;LINC00662;MIR4534;PCBP2-OT1;RP11-693J15.5
TAC1 (upregulated)hsa-miR-212-3pCASC7;CTB-89H12.4;NEAT1;RP11-26J3.3;XIST;XLOC_006753
Table 9

AD-associate miRNAs associated with other neurodegenerative disease-associate DEGs.

Other neurodegenerative disease-associate DEGsAD-associate miRNAslncRNAs associated with miRNAs
MAP1Ahsa-miR-24-3pCTA-292E10.9;CTC-273B12.8;GABPB1-AS1;LINC00662;LOC388692;MIR4534;RP11-54O7.1;XLOC_006242;XLOC_008461;XLOC_011313;
hsa-miR-497-5pAC005540.3;C1orf132;C1RL-AS1;FGF14-IT1;GS1-358P8.4;INO80B-WBP1;KCNQ1OT1;LINC00662;MIA-RAB4B;RP11-361F15.2;RP5-991G20.1;RP6-24A23.7;XIST;XLOC_006753;XLOC_008207;XLOC_013174;XLOC_013424
hsa-miR-15a-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;MCM3AP-AS1;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP5-991G20.1;RP6-24A23.7;XLOC_003546;XLOC_008207;XLOC_006753;XLOC_013174
hsa-miR-15b-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_008207;XLOC_013174
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
MLF2hsa-miR-200b-3pCTC-444N24.11;XIST;XLOC_013174
NARShsa-miR-15b-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_008207;XLOC_013174
ACADMhsa-miR-128-3p
hsa-miR-376a-5pKCNQ1OT1;SIK3-IT1
ACTL6Ahsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-18a-5pAC000403.4;CASC7;CTB-89H12.4;IPW;KCNIP4-IT1;KCNQ1OT1;LINC00506;N4BP2L2-IT2;RP11-10E18.7;RP11-1134I14.8;RP11-147L13.14;RP11-314B1.2;RP11-361F15.2;RP11-707A18.1;RP1-309I22.2;XLOC_003971;XLOC_010463;XLOC_011185;ZNF883;ZNRD1-AS1
hsa-miR-18b-5pXIST;XLOC_014102
AK3hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
AMOTL2hsa-miR-107CASC7;KCNQ1OT1;LINC00662;MIR4534;RP11-361F15.2;RP6-24A23.7;STAG3L5P-PVRIG2P-PILRB;XLOC_006753
hsa-miR-128-3p
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
ATG4Chsa-miR-128-3p
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-200b-3pCTC-444N24.11;XIST;XLOC_013174
hsa-miR-31-5pKCNQ1OT1;TSIX;XLOC_013174
hsa-miR-376a-5pKCNQ1OT1;SIK3-IT1
CAPS2hsa-miR-33a-5pCTC-444N24.11;KCNQ1OT1;MCF2L-AS1
FUT9hsa-miR-33a-5pCTC-444N24.11;KCNQ1OT1;MCF2L-AS1
HLA-DMAhsa-miR-200b-3pCTC-444N24.11;XIST;XLOC_013174
NUP133hsa-miR-128-3p
PCMTD2hsa-miR-200b-3pCTC-444N24.11;XIST;XLOC_013174
PLEKhsa-miR-107CASC7;KCNQ1OT1;LINC00662;MIR4534;RP11-361F15.2;RP6-24A23.7;STAG3L5P-PVRIG2P-PILRB;XLOC_006753
PPM1Khsa-miR-107CASC7;KCNQ1OT1;LINC00662;MIR4534;RP11-361F15.2;RP6-24A23.7;STAG3L5P-PVRIG2P-PILRB;XLOC_006753
hsa-miR-128-3p
hsa-miR-15a-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;MCM3AP-AS1;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP5-991G20.1;RP6-24A23.7;XLOC_003546;XLOC_008207;XLOC_006753;XLOC_013174
hsa-miR-15b-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_008207;XLOC_013174
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-24-3pCTA-292E10.9;CTC-273B12.8;GABPB1-AS1;LINC00662;LOC388692;MIR4534;RP11-54O7.1;XLOC_006242;XLOC_008461;XLOC_011313;
hsa-miR-497-5pAC005540.3;C1orf132;C1RL-AS1;FGF14-IT1;GS1-358P8.4;INO80B-WBP1;KCNQ1OT1;LINC00662;MIA-RAB4B;RP11-361F15.2;RP5-991G20.1;RP6-24A23.7;XIST;XLOC_006753;XLOC_008207;XLOC_013174;XLOC_013424
PRPF38Bhsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
QKIhsa-miR-107CASC7;KCNQ1OT1;LINC00662;MIR4534;RP11-361F15.2;RP6-24A23.7;STAG3L5P-PVRIG2P-PILRB;XLOC_006753
hsa-miR-128-3p
hsa-miR-15a-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;MCM3AP-AS1;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP5-991G20.1;RP6-24A23.7;XLOC_003546;XLOC_008207;XLOC_006753;XLOC_013174
hsa-miR-15b-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_008207;XLOC_013174
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-24-3pCTA-292E10.9;CTC-273B12.8;GABPB1-AS1;LINC00662;LOC388692;MIR4534;RP11-54O7.1;XLOC_006242;XLOC_008461;XLOC_011313;
hsa-miR-29a-3pAC005154.6;AC006548.28;H19;KCNQ1OT1;LINC00674;MIR4697HG;NEAT1;RP11-314B1.2;RP11-582E3.6;RP4-630A11.3;THUMPD3-AS1;TTTY15;TUG1;XLOC_004366;XLOC_007942;XLOC_008295
hsa-miR-375KCNQ1OT1;SNHG14;SNORD116-20
hsa-miR-497-5pAC005540.3;C1orf132;C1RL-AS1;FGF14-IT1;GS1-358P8.4;INO80B-WBP1;KCNQ1OT1;LINC00662;MIA-RAB4B;RP11-361F15.2;RP5-991G20.1;RP6-24A23.7;XIST;XLOC_006753;XLOC_008207;XLOC_013174;XLOC_013424
RNF19Ahsa-miR-107CASC7;KCNQ1OT1;LINC00662;MIR4534;RP11-361F15.2;RP6-24A23.7;STAG3L5P-PVRIG2P-PILRB;XLOC_006753
hsa-miR-29a-3pAC005154.6;AC006548.28;H19;KCNQ1OT1;LINC00674;MIR4697HG;NEAT1;RP11-314B1.2;RP11-582E3.6;RP4-630A11.3;THUMPD3-AS1;TTTY15;TUG1;XLOC_004366;XLOC_007942;XLOC_008295
SLC44A1hsa-miR-24-3pCTA-292E10.9;CTC-273B12.8;GABPB1-AS1;LINC00662;LOC388692;MIR4534;RP11-54O7.1;XLOC_006242;XLOC_008461;XLOC_011313
SPP1hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
STARD7hsa-miR-31-5pKCNQ1OT1;TSIX;XLOC_013174
hsa-miR-433-3p
STOMhsa-miR-107CASC7;KCNQ1OT1;LINC00662;MIR4534;RP11-361F15.2;RP6-24A23.7;STAG3L5P-PVRIG2P-PILRB;XLOC_006753
hsa-miR-128-3p
hsa-miR-15a-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;MCM3AP-AS1;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP5-991G20.1;RP6-24A23.7;XLOC_003546;XLOC_008207;XLOC_006753;XLOC_013174
hsa-miR-15b-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-361F15.2;RP11-96D1.10;RP3-508I15.20;RP6-24A23.7;XLOC_008207;XLOC_013174
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-497-5pAC005540.3;C1orf132;C1RL-AS1;FGF14-IT1;GS1-358P8.4;INO80B-WBP1;KCNQ1OT1;LINC00662;MIA-RAB4B;RP11-361F15.2;RP5-991G20.1;RP6-24A23.7;XIST;XLOC_006753;XLOC_008207;XLOC_013174;XLOC_013424
SUMF1hsa-miR-128-3p
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
TRIM22hsa-miR-107CASC7;KCNQ1OT1;LINC00662;MIR4534;RP11-361F15.2;RP6-24A23.7;STAG3L5P-PVRIG2P-PILRB;XLOC_006753
hsa-miR-31-5pKCNQ1OT1;TSIX;XLOC_013174
TSPAN6hsa-miR-107CASC7;KCNQ1OT1;LINC00662;MIR4534;RP11-361F15.2;RP6-24A23.7;STAG3L5P-PVRIG2P-PILRB;XLOC_006753
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
VPS13Chsa-miR-107CASC7;KCNQ1OT1;LINC00662;MIR4534;RP11-361F15.2;RP6-24A23.7;STAG3L5P-PVRIG2P-PILRB;XLOC_006753
hsa-miR-16-5pAC005540.3;FGF14-IT1;GS1-358P8.4;KCNQ1OT1;LINC00662;RP11-359B12.2;RP11-361F15.2;RP3-508I15.20;RP6-24A23.7;XLOC_003546;XLOC_006753;XLOC_008207;XLOC_013174
hsa-miR-186-5pCTA-292E10.9;CTB-89H12.4;CTC-428G20.3;MAGI2-AS3;MIR4534;NEAT1;OIP5-AS1;RP11-61A14.2;RP1-309I22.2;XIST
hsa-miR-29a-3pAC005154.6;AC006548.28;H19;KCNQ1OT1;LINC00674;MIR4697HG;NEAT1;RP11-314B1.2;RP11-582E3.6;RP4-630A11.3;THUMPD3-AS1;TTTY15;TUG1;XLOC_004366;XLOC_007942;XLOC_008295
AD-associate miRNAs associated with the AD-associate DEGs. Other neurodegenerative disease-specific miRNAs associated with the AD-associate DEGs. AD-associate miRNAs associated with other neurodegenerative disease-associate DEGs.

Analysis of miRNA Expression in AD by High-Throughput Data

To study the predicted expression of the AD-associated miRNAs further, a GEO dataset (GSE16759) studying miRNA was analyzed. This revealed 870 differentially expressed miRNAs. Detailed information on these miRNAs is shown in Table S7. Then, we analyzed the miRNAs common to both GSE16759 and our AD-associated miRNAs, and detected 47 of our AD-associated miRNAs in the GEO data. The top 12 significant miRNAs common to both GSE16759 and our AD-associated miRNAs are listed in Table 10.
Table 10

The top significant common genes in GSE16759 and our AD-associated miRNA.

IDadj.P-ValueP-ValuelogFC
hsa-miR-4240.08890.0011322−3.6568626
hsa-miR-376a0.10330.0068405−3.47133
hsa-miR-1860.10280.0025921−2.5463854
hsa-miR-148b0.10280.0061566−2.2428498
hsa-miR-1010.08890.000485−1.8992436
hsa-miR-3400.34010.1038393−1.7586512
hsa-miR-29b0.08890.0014182−1.6383336
hsa-miR-15a0.10280.0040077−1.524008
hsa-miR-1370.12620.0127089−1.4923006
hsa-miR-130a0.10280.0066478−1.4733294
hsa-miR-29c0.10330.0069833−1.4723696
hsa-miR-27a0.13750.0155005−1.011425
The top significant common genes in GSE16759 and our AD-associated miRNA.

The Transcription Factors Associated With the AD-Associated/Other Neurodegenerative Disease-Associated DEGs and miRNAs

By analyzing TF–gene regulation, we found 442 gene-associated TFs (gTFs) associated with 55 AD-associated DEGs (Table S8), and 400 gTFs associated with 42 other neurodegenerative disease-associated DEGs (Table S9). By studying the regulatory relationships between TFs and miRNAs, we obtained 253 miRNA-associated TFs (mTFs) associated with 50 AD-associated miRNAs (Table S10), and 118 mTFs associated with 22 other neurodegenerative disease-associated miRNAs whose target genes were identified as AD-associated DEGs in our study (Table S11).

mTF–miRNA–gene–gTF Regulatory Network

A regulatory network was constructed to study the regulatory interactions further, containing the AD-associated DEGs, the TFs associated with these genes (gTFs), the AD-associated miRNAs associated with these genes, the other neurodegenerative disease-associated miRNAs targeting these DEGs, and the TFs related to these miRNAs (mTFs). To study the other neurodegenerative disease-associated DEGs further, the TFs associated with these genes (gTFs), the AD-associated miRNAs targeting these genes, and the TFs related to these miRNAs (mTFs) were also analyzed. This showed that NFASC and ADAP1 are regulated by the most gTFs, 114 and 111, respectively. NFASC is involved in multiple sclerosis (Kawamura, 2014), and ADAP1 is involved in AD (Stricker and Reiser, 2014). We also found gTFs for the hub genes Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ribosomal protein S27a (RPS27A), Glial fibrillary acidic protein (GFAP), Beta-2 microglobulin (B2M), Clusterin (CLU), Eukaryotic elongation factor 2 (EEF2), Gap junction protein alpha 1 (GJA1), and Ceruloplasmin (CP). RAB10 and TUBB4B are regulated by the most miRNAs, 25 and 16, respectively. Both genes have been reported to be associated with AD (Olah et al., 2011; Martins-de-Souza et al., 2012). Analysis of the regulatory network identified the presence of 131 interesting feed-forward loops (FFLs) (Table S12), in which a TF controls a miRNA and together they coregulate a target gene. These 131 FFLs involved 22 DEGs (20 AD-associated DEGs and two other neurodegenerative disease-associated DEGs), 31 miRNAs (26 AD-associated miRNAs and five other neurodegenerative disease-associated miRNAs), and 28 TFs. It was interesting that an FFL was identified between the gene SERPINA3, hsa-miR-27a, and the TF MYC, shown in Figure 6. Interestingly, our study found that two other neurodegenerative disease-associated DEGs are involved in such FFLs between the gene STARD7, hsa-miR-433, and the TF SMAD3, the gene STARD7, hsa-miR-31, and the TF SMAD3, the gene TRIM22, hsa-miR-31, and the TF ELK1, the gene TRIM22, hsa-miR-31, and the TF SMAD3, and the gene TRIM22, hsa-miR-31, and the TF SOX4. Hsa-miR-433 and hsa-miR-31 have already been reported to be associated with AD. Therefore, the associations between AD and the genes STARD7 and TRIM22 were studied further.
Figure 6

The interaction network among a FFL nodes. The triangle-shaped node represents miRNAs, ellipse-shaped node represents genes, and diamond-shaped node represents transcription factors (TFs).

The interaction network among a FFL nodes. The triangle-shaped node represents miRNAs, ellipse-shaped node represents genes, and diamond-shaped node represents transcription factors (TFs).

Verification of FFL Between the Gene SERPINA3, hsa-miR-27a, and TF MYC

GEO dataset (GSE16759) studying mRNA and miRNA was analyzed. This result revealed that SERPINA3 and MYC are upregulated, and hsa-miR-27a is downregulated in AD patients compared with controls. Detailed information is shown in Table 11.
Table 11

The expression the gene SERPINA3, hsa-miR-27a, and TF MYC from FFL in different datasets.

Gene/miRNA symbolGSE16759GSE97760(mRNA)/GSE46579(miRNA)
adj.P-ValueP-ValuelogFCadj.P-ValueP-ValuelogFC
SERPINA30.9990.66988360.411914640.0008780.00004812.3410491
MYC0.9880.21504540.436307280.5410.323−0.3806443
hsa-miR-27a0.13750.0155005−1.0114250.429179030.576982734−0.187196408
The expression the gene SERPINA3, hsa-miR-27a, and TF MYC from FFL in different datasets. To further verify the results, GSE46579 dataset studying miRNA expression in AD patients and controls blood was analyzed. Hsa-miR-27a was shown downregulated in AD patients blood. GSE97760 dataset studying mRNA expression was analyzed. The expression of SERPINA3 was shown upregulated, however MYC was shown downregulated. Detailed information is shown in Table 11. SNPs corresponding to the AD-associated DEGs were obtained from the MirSNP online database. This showed that 1051 miRNAs were related to these SNPs, of which 79 miRNAs were AD associated. The results showed that 173 SNPs were related to these 79 miRNAs, and these 173 SNPs were associated with 40 AD-associated DEGs identified in our study. The chromosome loci information of these 173 SNPs is shown in Table S13.

Discussion

In the past decades, research on the progression of AD has been productive, however identification of more potential genes and pathways in the pathogenesis of AD is needed. Therefore, large sample studies are essential for studying the effects of genes on the development of AD, and meta-analysis allows new biological insights. In this study, we obtained DEGs by meta-analysis merging several AD-related microarray gene expression studies. This resulted in eight hubs with high degree and closeness centrality values, which are GAPDH, RPS27A, GFAP, B2M, CLU, EEF2, GJA1, and CP. GAPDH co-localizes with most neurofibrillary tangles in the AD brain, and co-immunoprecipitates with abnormal tau antibodies in AD (Wang et al., 2005). The expression level of GAPDH in blood samples from familial AD patients is decreased compared with healthy controls (El Kadmiri et al., 2014). RPS27A, a component of the 40S subunit of the ribosome, are associated with AD (Soler-Lopez et al., 2011). GFAP, an astrocyte-specific intermediate filament, is significantly increased in AD mouse models compared with wildtype mice (Kamphuis et al., 2012). B2M is the light chain of the first major histocompatibility (MHC) antigen. Increased plasma B2M results in deposition of amyloid fibrils, which is associated with over 20 degenerative diseases, including AD (Kardos et al., 2004). CLU protein, an apolipoprotein, is responsible for clearing amyloid peptide and has neuroprotective effects for AD (Karch and Goate, 2015). EEF2 is significantly decreased in AD compared with controls (Li et al., 2005). GJA1, also known as connexin 43, shows upregulated mRNA and protein levels in AD (Ren et al., 2018). Specific deletion of astroglial connexin 43 in AD mice improved cognitive dysfunction (Ren et al., 2018). CP, a ferrous oxidase enzyme, plays an important role in regulating iron metabolism and redox reactions. CP expression was significantly downregulated in the hippocampus region of AD patients, resulting in memory impairment and increased iron accumulation (Zhao et al., 2018). However, the role of these genes in AD is not very clear. The importance of these genes requires further study in AD. Studies also have shown that there is a difference between different sexes in neuroanatomy and function, so gender differences may be of great significance in the treatment of AD (Moradifard et al., 2018). More and more attention has been paid to the gender differences in AD prevalence. Some evidence showed that the risk of AD due to APOE ε4 allele is different in two sexes: female carriers are at higher risk of AD than male carriers (Nyarko et al., 2018). Based on our results, there are also a number of genes which specifically expressed in male and female. Such as CHC22 protein encoded by CLTCL1 gene was strongly suggested to play important function in affecting neuronal progenitor cells or immature neurons, and CLTCL1 was significantly upregulated in the development of human brain, especially cerebral cortex (Nahorski et al., 2015). LPIN1 plays a role in abdominal obesity, insulin sensitivity, and hypertriglyceridemia and it is associated to blood pressure regulation, especially in men (Ong et al., 2008). FOLR1 was reported to be overexpressed in ovarian cancer (Lin et al., 2013), and its expression could be regulated by both female sex hormones and retinoic acid (Kelemen et al., 2014). ELAVL2 might be critical for normal neuronal and synaptic function in the brain by regulating important genetic pathways participated in human neurodevelopment (Berto et al., 2016). Analysis of FFL identified the bioregulatory relationship between the gene SERPINA3, hsa-miR-27a, and the TF MYC. TransmiR information revealed that hsa-miR-27a is repressed by the TF MYC. By combining the results of the DIANA-LncBase and TRANSFAC databases, both MYC and hsa-miR-27a were found to regulate the target gene SERPINA3. The expression of hsa-miR-27a is downregulated in AD patients compared with controls (Nunez-Iglesias et al., 2010), this result is also verified in our study and GSE46579 dataset (Table 11). MYC is also physiologically relevant and is increased in vulnerable neurons in patients with AD (Ferrer et al., 2001). This suggests that this TF may be highly expressed in the brain tissues of AD patients, indicating that MYC downregulates hsa-miR-27a. SERPINA3 is also involved in AD (Guan et al., 2012) and was detected to be upregulated in our study. Therefore, this validates our findings in AD. It also verifies that MYC and SERPINA3 have an activation relationship. This activation relationship is also verified in the GEO dataset GSE16759. However, in GSE97760, the result is different to ours and GSE16759, which may be due to different samples (The samples in GSE16759 were the tissues, however the samples in GSE97760 were blood). There were 173 SNPs identified as being associated with 40 AD-associated DEGs, which were in turn regulated by AD-associated miRNAs. This enhances the relevance of these 173 SNPs in AD (Table S13). The function of these 173 SNPs was further analyzed using the SNP annotation tool SNPnexus (http://snp-nexus.org/index.html) (Dayem Ullah et al., 2018). Several SNPs related to hsa-miR-27a were identified. Among them were SNPs rs76463641 and rs79339279, located at the BRSK2 and GNB5 loci, respectively, which are both already known to be AD-associated genes (Katsumata et al., 2019). Therefore, hsa-miR-27a may be an important AD epigenetic biomarker in our study. Furthermore, our study identified several SNPs associated with five other neurodegenerative disease-associated miRNAs involved in FFL of the regulatory network. Interestingly, SNPs associated with hsa-miR-34c, hsa-miR-212, hsa-miR-34a, and hsa-miR-7 are located at known AD-associated gene loci. Thus, these four miRNAs may be associated with AD, although this requires further study for confirmation. Although this study is strict, it has some limitations. As the power of gene analysis is affected by the sample size, especially the number of cases, the current study may not have the strongest power. In addition, not all brain regions were studied. The other limitation is that only one dataset on the HIP brain region was selected to validate the microarray results, as RNA-Seq data for the other brain regions we studied (EC and MTG) in AD is lacking. So, further study is required, possibly with larger sample sizes, more brain regions. Considering the latent effects of the identified biomolecules in the pathogenesis of AD, experimental studies should be conducted to determine the possible roles of these molecules, but are lacking. In addition, the FFL between the gene SERPINA3, hsa-miR-27a and the TF MYC possibly provides new candidates for treatment of AD, so further experimental verification is needed.

Conclusion

In this study, based on high degree and closeness centrality values in the gene expression network, eight hub genes were identified, all of which have been reported to be associated with AD. By analyzing the mTF-miRNA-gene-gTF regulatory network, 131 FFLs were identified, in which an important FFL between the gene SERPINA3, hsa-miR-27a, and the TF MYC was identified. Further study on the lncRNA-mediated regulatory network suggested that these lncRNAs may be significant in AD, and these have not been found in previous studies. Moreover, 173 important SNPs were identified by SNP analysis, which may be helpful for predicting AD at an earlier stage.

Data Availability

All the data supporting the results of this study are included in the manuscript and the related Supplementary Documents.

Author Contributions

LS and HW designed the study. LS, SC, CZ, HW, and XS performed the data analysis. LS wrote the manuscript. HW supervised this work. All authors read and approved the final manuscript.

Conflict of Interest Statement

CZ was employed by company Shenzhen RealOmics (Biotech) Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Down- regulatedHippocampus (HIP)
GSE5281GSE36980GSE48350GSE29378GSE1297
log2FoldChangeP-Valuelog2FoldChangeP-Valuelog2FoldChangeP-Valuelog2FoldChangeP-Valuelog2FoldChangeP-Value
RPS27A−0.7266534450.0370789980.0064180530.6347916020.1622730620.001592564.70E-050.0066048280.2240134880.913570635
Up-regulatedlog2FoldChangeP-Valuelog2FoldChangeP-Valuelog2FoldChangeP-Valuelog2FoldChangeP-Valuelog2FoldChangeP-Value
PCSK1N0.1380697890.50703397−0.0313611770.057833175−0.2335328890.187009896NA−0.5623657040.177607105
MT1M0.7050829520.0927007610.0470283450.2827878290.1258373650.7392040260.1340122690.872273811−0.575943490.430641885
GJA10.3218463850.4239702040.046361560.176170552−0.0467123450.743685092-0.0172383430.4445463040.032887860.614266746
Down- regulatedEntorhinal Cortex (EC)
GSE5281GSE26927GSE48350
log2FoldChangeP-Valuelog2FoldChangeP-Valuelog2FoldChangeP-Value
ADAP1−0.9753587710.000738556−0.105989920.43225350.261772150.008467065
BRSK2−2.8779466442.47E−05−0.054922110.66499160.4717087050.012467794
DMTN−1.4248081118.99E−060.013191220.94213180.2359902210.191857188
DNM1−2.7398797872.39E−070.045399060.82201790.1500421320.156014246
FXYD7−1.9270202520.000125670.129067130.40242160.4219285390.067078593
GAPDH−1.8764465351.83E−050.106650210.41251550.1312086650.071996601
GNAS−2.1684317950.003326198−0.550141040.32134580.1010055490.082500384
GNB5−2.6294994590.0001437280.052596370.62208570.2678689450.177291265
HCFC1R1−2.4185752080.0015772450.072726770.76723560.2915745730.001166783
INA−2.2137901180.0002860980.158237940.43684170.230250250.29758798
L1CAM−2.2537192433.32E−080.092556050.68132470.2151780490.254031866
MLST8−1.0808128670.000603178−0.121081120.33250450.2877240120.005909275
NDUFV3−2.4564367630.000139382−0.044683960.83691190.2902096150.000799514
NRGN−1.936286330.004325631−0.119813460.53484170.3355877220.181571319
PCSK1N−2.755436136.15E−050.030894220.85351320.3068345360.041926028
RAD23A−1.4866861781.19E−05−0.069852490.46575110.1559191270.023202481
RPH3A−2.2053891280.000121979−0.136363540.55496910.4215800710.13750631
SLC17A6−1.8305520510.001580552−0.033246850.8169870.4642660730.117376592
SYN1−2.2996734621.58E−050.028893280.94643930.4526662930.078849751
TOMM40−0.7368302950.0159928490.309033010.49347360.1463210590.022047574
TUBB4B−2.6799878780.0003191790.070673930.44996490.2765539020.062125723
Up-regulatedlog2FoldChangeP-Valuelog2FoldChangeP-Valuelog2FoldChangeP-Value
ADAP20.512832870.118857833-0.066597970.80992460.2268337870.23714665
APBB1IP0.5875844340.084938225−0.008963420.9812134−0.0794414810.661738945
ARFGAP31.2362831590.0232864820.090211960.4114407−0.0356643450.74369762
ATRAID0.6253940240.3162120.234236020.1543085−0.0442804640.76558655
B2M1.4479359730.076662517−0.342085790.2037221−0.0415995630.71977472
CAPN20.848247280.0532656410.171518790.2941073−0.2134664130.179983124
CLU0.4785295190.322071446−0.25734370.0879138−0.0249101050.955459054
CP0.7098862750.181039467−0.789742740.11191820.1019470770.871136325
DYNLT10.8182643140.0799155030.051074430.725406−0.0201837550.897716773
FAM133B0.7784705340.051976016−0.212165330.0908713−0.2476617480.019678966
GFAP0.8007837030.036506933−0.216067560.5421759−0.003869050.989972713
HSPB80.4967662530.0771070610.044985350.8190471−0.0772199120.830926271
IGSF60.5011894690.262839015−0.276320740.4853182−0.0679402310.758869601
IQCK0.3339642980.13445688−0.115926610.371691−0.0616557790.581519573
LAP30.8976427770.145483073−0.243903160.25069340.0108337580.940660335
MAN2A10.7470023230.172935628−0.141575960.5729284−0.6822717260.054038553
MEGF100.5569936860.116067563−0.110603190.5623855−0.3361832880.089069161
NPL0.4467222650.1313615430.003112470.9926684−0.0785511650.757780969
PLXDC20.5085427480.14792643−0.29406960.2734916−0.2343375940.176238219
PRDX10.7660306120.301038221−0.104691490.31290330.0005178660.995942177
PRDX60.7603141790.091473535−0.088194970.5972124−0.0281798090.882624237
RAB100.4422052850.105401194−0.003278920.9775461−0.0210163680.747519625
SERPINA31.7780458850.153542154−0.70743980.31067790.531383780.379307158
SLC16A9−0.0833978680.891622356−0.018957440.9275386−0.1338897260.776238048
SRSF60.5891498270.1723260710.006693090.9432160.1261914870.600178046
TAC11.9953036870.2020419970.193671330.5835214−0.5231565720.688917746
WDR110.8113091060.0608647910.133362140.3471851−0.354303920.019054577
Down- regulatedMedial temporal gyrus(MTG)
GSE5281GSE84422
log2FoldChangeP-Valuelog2FoldChangeP-Value
MT30.4719719010.069615230.0062647330.376461879
SEPP10.9522434960.0497735280.0255327980.310596068
NME20.2532725440.2954141630.0075409230.012257472
EEF20.4500312330.08246170.0006332390.600645423
  17 in total

1.  Meta-Analysis of Gene Expression Changes in the Blood of Patients with Mild Cognitive Impairment and Alzheimer's Disease Dementia.

Authors:  Virginie Bottero; Judith A Potashkin
Journal:  Int J Mol Sci       Date:  2019-10-30       Impact factor: 5.923

2.  Regional Differences in Neuroinflammation-Associated Gene Expression in the Brain of Sporadic Creutzfeldt-Jakob Disease Patients.

Authors:  Aušrinė Areškevičiūtė; Thomas Litman; Helle Broholm; Linea C Melchior; Pia R Nielsen; Alison Green; Jens O Eriksen; Colin Smith; Eva L Lund
Journal:  Int J Mol Sci       Date:  2020-12-25       Impact factor: 5.923

3.  RPL6: A Key Molecule Regulating Zinc- and Magnesium-Bound Metalloproteins of Parkinson's Disease.

Authors:  Athira Anirudhan; Paola Isabel Angulo-Bejarano; Prabu Paramasivam; Kalaivani Manokaran; S Manjunath Kamath; Ram Murugesan; Ashutosh Sharma; Shiek S S J Ahmed
Journal:  Front Neurosci       Date:  2021-03-11       Impact factor: 4.677

4.  Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies.

Authors:  Namshik Han; Woochang Hwang; Konstantinos Tzelepis; Patrick Schmerer; Eliza Yankova; Méabh MacMahon; Winnie Lei; Nicholas M Katritsis; Anika Liu; Ulrike Felgenhauer; Alison Schuldt; Rebecca Harris; Kathryn Chapman; Frank McCaughan; Friedemann Weber; Tony Kouzarides
Journal:  Sci Adv       Date:  2021-06-30       Impact factor: 14.136

Review 5.  Deregulation of ncRNA in Neurodegenerative Disease: Focus on circRNA, lncRNA and miRNA in Amyotrophic Lateral Sclerosis.

Authors:  Paola Ruffo; Claudia Strafella; Raffaella Cascella; Valerio Caputo; Francesca Luisa Conforti; Sebastiano Andò; Emiliano Giardina
Journal:  Front Genet       Date:  2021-12-02       Impact factor: 4.599

Review 6.  A description of the relationship in healthy longevity and aging-related disease: from gene to protein.

Authors:  Xiaolin Ni; Zhaoping Wang; Danni Gao; Huiping Yuan; Liang Sun; Xiaoquan Zhu; Qi Zhou; Ze Yang
Journal:  Immun Ageing       Date:  2021-06-25       Impact factor: 6.400

7.  Metabolomic and transcriptomic signatures of prenatal excessive methionine support nature rather than nurture in schizophrenia pathogenesis.

Authors:  Siwei Chen; Wedad Alhassen; Ryan Yoshimura; Angele De Silva; Geoffrey W Abbott; Pierre Baldi; Amal Alachkar
Journal:  Commun Biol       Date:  2020-07-30

8.  Perinuclear Lamin A and Nucleoplasmic Lamin B2 Characterize Two Types of Hippocampal Neurons through Alzheimer's Disease Progression.

Authors:  Laura Gil; Sandra A Niño; Erika Chi-Ahumada; Ildelfonso Rodríguez-Leyva; Carmen Guerrero; Ana Belén Rebolledo; José A Arias; María E Jiménez-Capdeville
Journal:  Int J Mol Sci       Date:  2020-03-07       Impact factor: 5.923

9.  Pravastatin-induced changes in expression of long non-coding and coding RNAs in endothelial cells.

Authors:  Shweta Singh; Hien C Nguyen; Mehroz Ehsan; David C R Michels; Priyanka Singh; Mohammad Qadura; Krishna K Singh
Journal:  Physiol Rep       Date:  2021-01

10.  Genetically regulated expression in late-onset Alzheimer's disease implicates risk genes within known and novel loci.

Authors:  Hung-Hsin Chen; Lauren E Petty; Jin Sha; Yi Zhao; Amanda Kuzma; Otto Valladares; William Bush; Adam C Naj; Eric R Gamazon; Jennifer E Below
Journal:  Transl Psychiatry       Date:  2021-12-06       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.